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Polymorphic expression of the arylamine N—acetyltransferases (NAT)
In humans has been correlated with genetic predisposition to bladder
cancer, but the molecular basis for the differential susceptibility is
not fully understood. The inbred Syrian hamsters used In this study,
with clearly defined acetylator genotypes, expressed acetylator genotype—
dependent NAT activity in crude and partially purified bladder cytosol,
with apparent Vmax about 6— to 46—fold higher in rapid acetylators,
concordant with genotypic expression of hepatic NAT activity. Parallel
in vivo and in vitro genotoxicity assays detected higher levels of
hepatic arylamine—DNA adducts (1.5— to 2.3—fold) and mutagenic acti
vation (2—fold) in slow than in rapid acetylator hamsters. The results
suggest a critical modulating effect of the N—acetylation polymorphism
on arylamine—induced genotoxicity and may be a critical factor in
determining susceptibility to arylamine—Induced bladder cancer.
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Interest In the metabolism of arylamines was initially generated
following the association of this class of chemicals to the incidence of
drug—induced toxicities and cancer. Occupational exposure to arylamines
such as benzidine~ beta—naphthylamine, 4—aminobiphenyl and methylene—
bischronoanhline used in synthesizing dyes for consumer goods, has
convincingly been established as the causal agent in urinary bladder
cancer in humans, by Case et al. (1954) and Veys (1969). Animal studies
have also shown that arylamines are carcinogenic and that there exist
species and organ specificities (Clayson and Garner, 1976; Radomski,
1979). In man, the rate of metabolism of drugs and chemical carcinogens
is subject to large Interindividual differences, due to the
contributions of a number of factors. Genetic constitution of enzymes
of metabolism Is now recognized as one of the major contributing
factors. Thus, the delicate balance in each tissue between enzymes
which activate and enzymes which detoxify highly reactive carcinogenic
arylamine metabolites may be effectively altered by heritable
differences in the capacity for enzyme activity.
1
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The metabolic steps involved in arylamine activation/deactivation
have been extensively studied and some Important steps identified.
Generally, N—oxidation catalyzed by microsomal monooxygenases
(cytochrome P—450) is recognized as an obligatory step (Frederick at
al., 1982), followed by enzyme mediated conjugation with glucuronic
acid, sulfate or acetate. Further enzymatic or non—enzymatic processes
may then lead to ultimate carcinogenic metabolites, which are usually
highly electrophilic, reacting with DNA (Miller and Miller, 1981; KIng
and Glowinski, 1983), to exert their deleterious effect.
In animal species with little or no cytochrome P—450 activity in
extrahepatic tissue, such as the dog bladder, PHS—catalyzed peroxidative
oxidation has been suggested to serve as an alternative activating
system in arylamine—induced bladder carcinogenesis (Zenser et al., 1980;
Kadlubar et al., 1982; Wise at al., 1984). The PHS—catalyzed activation
of arylamines is thought to involve oxidation via an one—electron
mechanism (Boyd et al., 1983), resulting in free radicals or free
radical—derived species that are capable of binding to DNA (Krans and
Eling, 1985), or are mutagenic in modified Ames tests (Boyd at al.,
1985).
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The biologic N—acetylatiofl reaction in mammals is limited almost
entirely to arylamines and hydrazines. This reaction is catalyzed by
cytosol ic AcCQA—dependent N—acetyltraflSferaSe (NAT) enzymes.
N—acetylatiofl capacity exhibits a well—defined genetic variation in
humans (Evans et al., 1960) and several other mammalian species,
including hamsters (Hem et al., 1982). Individuals are classified
phenotypically as slow, intermediate or rapid acetylators. Two separate
peaks of NAT activities have been partially purified from hepatic
(Trinidad et al., 1989) and bladder (Yerokun et al., 1989) cytosolic
preparations from both homozygous rapid and slow acetylator hamsters.
Using PABA, PAS, AF, ABP and BNA as substrates, the first eluting NAT
isozyme (PAT), derived from hamster liver and bladder, exhibited
activities that were acetylator genotype—dependent, while the second
eluting NAT isozyme (MAT) exhibited similar activities across the rapid
and slow acetylator genotypes (Hem et al., 1987; Trinidad et al., 1989;
Yerokun et al., 1989). The PAT isozyme is thought to be responsible for
the acetylator genotype—dependent NAT activity expressed In crude tissue
cytosols. The apparent Vmax for AF N—acetylation by PAT activity in
rapid acetylator bladder was substantially greater (50—fold) than in the
slow acetylator. Similarly, about 7— to 10—fold differences have been
observed in hamster liver preparations (Trinidad et al., 1989).
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The functional capacity of enzyme systems Involved in the metabolic
pathway of arylamine drugs and carcinogens often helps determine both
species and tissue susceptibility to arylamine—Induced toxicities and
carcinogenesis (reviewed in Weber and Hem, 1985). For example, human
epidemiological studies have associated the slow acetylator phenotypes
with significantly more frequent Incidence of bladder cancer, compared
to healthy control groups (Lower et al, 1979; Cartwrlght et al., 1982.
Evans et al., 1983; Hanssen et al., 1985). Characterization of the
genetic acetylation polymorphism and the NAT enzymes will be required
for a full understanding of the relationship between the N—acetylatlon
polymorphism and the molecular basis for differential susceptibility to
arylamine—induced bladder cancer. It has been suggested that the
critical role for NAT Is in the detoxification of carcinogenic species
metabolized from N—substituted aryl compounds (Lower and Bryan, 1973).
Therefore, the relative rates of NAT catalyzed acetylation reactions may
be a critical factor affecting the levels of reactive metabolites
generated and consequently, susceptibility to arylamine—Induced
genotoxicity In select organs and tissues.
Although it is difficult to monitor the production of all reactive
metabolic derivatives In biological systems, their formation can be
conveniently monitored using DNA binding assays (Beland et al., 1979;
Hsu et al., 1981; Perera et al., 1982; Gupta et al., 1982).
~il ~ IIIi~~J I
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The recently developed [32P]—postlabeling thin layer chromatography
assay technique provides a very sensitive procedure for monitoring low
levels of DNA adducts in target tissues following exposure to chemical
carcinogens, and can be a reliable probe of metabolic activation of
carcinogenic arylamines.
Arylamine—nucleic acid adduct formation results directly from the
spontaneous coupling of arylnitrenium or arylamidonium ions with nucleic
acid. N—hydroxyarylamines readily react with DNA at slightly acidic pH
and are carcinogenic (Kadlubar et al, 1977), as well as acting as
direct mutagens (McCann et al., 1977). The majority of adduct species
are usually attached to deoxyguanosine (Beland et al., 1983). Three
predominant species of hepatic arylamine DNA—adducts have been
identified following exposure of experimental animals to arlyamines.
These include the N—(deoxyguanosin-8—yl)—arylamjne adduct which
constitutes the major adduct species, while the N—(deoxyguanosin—8—yl)--
acetylarylamine and the 3—(deoxyguanosjn—N2—yl )—acetylarylamine adduct
species are found as minor adducts (Westra and Visser, 1979; Beland et
al., 1980). It Is recognized that the extent of interaction of
chemicals or their metabolites to DNA correlates with carcinogenic
potential (Brookes, 1.966). In a study by Gupta et al. (1984), it was
observed that a major C8—guanine deacetylated adduct appeared to persist
for over twenty four hours following the treatment of male Sprague
lIII~il~ Ii
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Dawley rats with N—hydroxylated acetylamlnofluorene. Although the
covalent binding of carcinogens to DNA Is recognized as one of the
critical events in chemical carcinogenesis, there is much less certainty
about the reactions that Intervene between this binding and cellular
transformation. N—acetylation can possibly modulate the carcinogenic
potential of arylamines by effectively perturbing the metabolic
activation step, reducing the concentration of reactive arylamine
derivatives that can covalently bind to DNA. Thus, differences In
acetylator status may be reflected in differential susceptibility to
genotoxicity.
A high empirical correlation has been measured between mutagenicity
in bacteria and genotoxicity in higher organisms (Leifer et al., 1981)
The Ames Salmonella test (Ames et al., 1975) is recognized as a
sensitive assay procedure for evaluating the potential mutagenicity/—
carcinogenicity of natural chemicals and xenoblotics Including
arylamines. This test measures the frequency of back mutation of a
histidine—requirlng tester strain of Salmonella tyDhimurium. Due to the
fact that a majority of chemical carcinogens require metabolic
activation In order to manifest their mutagenic/carcinogenic properties,
mammalian activation systems are Incorporated in the Ames and other
mutagenicity tests (Marion and Ames, 1983). The standard activation
7
system comprises hepatic or extrahepatic mitochondrial supernatant (S9),
fortified with a NADPH—regenerating system This mammalian activation
system compensates for the limited capability of the tester bacteria
cells to metabolize carcinogens. It also allows for differential
expression of mutagenicity due to inter—individual or inter—species
differences in the modulation of metabolic activation of the carcinogen.
Thus, this test procedure was used to assess the modulating effect of
acetylator genotype on the mutagenic activation of AF, using a TA98
Salmonella tvDhlmurium tester strain. In the present studies, the
relative capacity of bladder tissues from homozygous slow and homozygous
rapid acetylators, as well as, heterozygous Fl progeny Syrian hamsters
for AcCoA—dependent N—acetylation catalyzed by N—acetyltransferase was
determined In cytosolic and partially purified fractions. In addition,
correlations between acetylator genotype, arylamine DNA adduct levels
and modulation of mutagenic activation of AF were assessed.
CHAPTER II
REVIEW OF LITERATURE
Persøectives on Human ExDosure to Arvlamines
Aromatic amines or arylamines, as they are convnonly referred to,
and hydrazine drugs have been and continue to be chemotherapeutic drugs
used In the treatment of a diverse array of diseases including
hypertension, which Is often treated with hydralazine, cardiac
arrythmias (procainamide), tuberculosis (isoniazid), leprosy and
dermatitis herpeformis (dapsone), mental depression (phenelzine), and
chronic inflammatory disorders (sulfasalazine) (reviewed in Weber,
1987). However, incidences of toxicities induced by some of these drugs
have been reported. Liver toxicity secondary to isoniazid therapy has
been observed (Camba, 1953; Grimmin.ger, 1953; Cohen et al, 1961). The
potentially fatal severity of this toxicity was later reported by
Garibaldi et al.(1972), following an outbreak of mortalities associated
with the administration of the drug. Isoniazid—induced neurotoxicity
has also been reported (Hughes et al., 1954; Biehi and Nimitz, 1954),
while peripheral neuropathy has also occurred as a rare complication of
dapsone therapy (Waldinger et al.,.1984). Long—term administration of
procalnamide is now limited by the occurrence of a toxic condition
resembling systemic lupus erythmatosus (Reidenberg, 1981).
8
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Arylamines are also used as intermediates in the synthesis of
organic compounds, such as azo dyes and anti—oxidants (Wynder et aL,
1963). They are found as environmental and industrial wastes released
in protein and organic matter pyrolysis prodi.zcts. Industrial chemicals
such as benzidlne, beta—naphthylamine, 2—aminofluorene, 4—aminobiphenyl
have been used for more than a hundred years in the dye and rubber
industry (Cartwrlght, 1983). tn 1933, a member of the arylamine class
of chemicals, dlbenz(a)anthracene was purified and established as a
major cancer component of coal tar, by Kennaway and coworkers (Cook et
al.,, 1933; Cook and Kennaway, 1938). More recently, similar chemicals
such as methylene—bis--2—chronoaniline and certain other derivatives of
aniline as well as hydrazine have come Into use in the manufacture of
plastics, dyes, insulators, rubber products and rocket propellants.
Exposures to these compounds have also been implicated In bladder cancer
In humans and experimental animals (Case et al., 1954; Veys et al.,
1969; Johannsen et al., 1974). OccupatIonal exposure to arylamines was
convincingly established as the causative factor in urinary bladder
cancer of exposed workers by the study of Case and co—workers (1954).
~U kiIl~d~ hi
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Several mutagenic heterocyclic arylamines, broadly categorized into
carboline compounds such as 2—amino—6—methydipyridol[1 ,2—a:3’ ,2’—
d]imidazole (Glu—P—1) and 3—amlno—1,4—dimethyl—5H—PYridO[4,3—b]ifldole
(Trp—P—1) and aminoimidazo—quinoline—type compounds such as 2—amino—3—
methylimldazo[4,5—f]quinoline (IQ) , have been detected In pyrolysis
products formed from cooked food, heat—processed fish, proteins and
amino acids (Commoner et al., 1978; Sugimura, 1982; BjeIdanes et al,
1983; Felton et al., 1984; Hatchet al., 1984). Trp—P—1 and Qlu—P—1 have
chemical structures that are similar to the prototype arylamine
carcinogen AF, while the structure of IQ is similar to that of 3,2’—
dimethyl—4—aminobiphenyl (DMABP), a potent colon carcinogen in man
(Walpole et al. 1972) . DMABP is also used in Inducing cancer in
experimental animal models including hamsters (Spiut and Spratt, 1965;
So et al., 1972; Williams et al., 1981). Generally, heterocyclic
arylamines have metabolic pathways similar to those of non—heterocyclic
arylamines. Cytochrome P—450—catalyzed N—hydroxylation Is also
considered to be an obligatory step in their metabolic activation
(Felton et al., 1981; Mita et al, 1981; Kato, 1986). Although these
compounds are known to be produced In small quantities during cooking
(Felton et al., 1984), they are highly potent mutagens in Salmonella
typhimurium, after metabolic activation by hepatic homogenates
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(Sugimura and Nagao, 1982). N—acetylation has been shown to decrease
the mutagenecity of some heterocyclic arylamines (Nagao et al., 1980).
Furthermore, species differences in the acetylation of mutagenic
heterocyclic arylamines by liver cytosol has been reported (Shinohara et
al., 1984). The N—acetylation reaction may also be competing with the
N—hydroxylation reaction in the metabolism of these chemical species
Studies have also shown that heterocyclic arylamines can be
0—acetylated, an enzyme—catalyzed reaction that has been implicated in
the activation of arylamines to highly electrophilic colon carcinogens
(Flammang et al., 1985; Saito et al., 1986). The ability of IQ to
induce neoplastic transformation of mouse embryo fibroblasts has also
been demonstrated (Cortesi and Dolara, 1983).
Cigarette smoke is a recognized cause of bladder cancer (Parkers
and Evans, 1984), thought perhaps to be due to the presence of minute
quantities of certain arylamines present in cigarette smoke (Hoffman et
al., 1969). The arylamine bladder carcinogens ABP and BNA have been
detected in cigarette smoke and are thought to be the major contributing
factor to the higher frequency of bladder cancer among smokers.
Occupational and environmental exposure to polychiorinated hydrocarbons
and arylamines are implicated in chemical—induced urinary bladder cancer
(Lower, 1982). From these beginnings, awareness of the human risk for
• ~ II~~ b I
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cancer arising from exposure to arylamines has rapidly progressed.
Human exposure to carcinogenic arylamines continues to occur from both
occupational and environmental sources, including, cigarette smoke,
synthetic fuel, and diesel exhaust (Hoffman et al., 1982; Tokiwa and
Ohnishl, 1986).
Metabolic Reauirement for Arviamine Carclnpgenlclty
Early reports associating arylamines to the Incidence of cancer
also observed that these chemicals usually induce tumors in excretory
tissues such as the liver, urinary bladder, and intestinal tract, rather
than at the sites of ingestion or administration. Thus, their
carcinogenic activities are now considered to be largely dependent on
metabolic activation by enzymes of the host (Miller and Miller, 1969).
The first proof of the molecular mechanism for this carcinogenic
response was reported by Miller and Miller (1952), who discovered that
carcinogenic arylamine derivatives combine covalently with cellular
macromolecules of susceptible tissues. Numerous studies now provide
evidences showing that the initiation of the process of carcinogenesis
occur when arylamines are metabolically activated to electrophilic
species that are more mutagenic and carcinogenic than the parent
compound (Irving, 1979; Miller and Miller, 1981; Kadlubar et al, 1986).
~i.UhI~~ h
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The induction of tumors at a number of sites in a variety of
experimental animals has been demonstrated, using arylamines (Radomski,
1979; Miller and Miller, 1983). Although the initiation of chemical
carcinogenesis often involve metabolic activation, detoxification occurs
simultaneously and the biologic effect reflects a balance between
activation and detoxification reactions. Animal studies provide
evidence showing that there exists species and organ specificity for
arylamine—induced carcinogenicity (Clayson and Garner, 1976). In man,
the rate of metabolism of drugs and chemical carcinogens is sub3ect to
large inter—individual differences due to the contribution of a number
of factors; heritable differences in the capacities of the enzymes of
metabolism is recognized as one of these factors.
Metabolic Pathways for Arviamines
The mammalian liver is recognized as the primary site of activation
of several chemical carcinogens. However, recent reports indicate that
the metabolism of carcinogens by peripheral target tissues do occur.
Tissue preparations from different extrahepatic organs including lung
(Cohen et al., 1976; Autrup et al., 1978), mammary gland (Grover et al.,
1980), gastrointestinal mucosa (Autrup et al, 1978 and 1980), skin
(MacNicoll et al., 1980) and bladder (Autrup et al., 1981;
~III~~ I
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Mattano and Weber, 1987; Hem et al., 1987b), have been shown to be
capable of metabolizing arylamines. Bladder urothelial cells from
various experimental animals including hamsters are known to be capable
of metabolizing a wide variety of chemicals such as nitrofurans,
nitroaromatics and polycyclic aromatic hydrocarbons (Autrup et al.,
1981; Mattano and Weber, 1987; Hem et al., 1987a).
Many different enzymes have been identified which contribute to the
metabolism of arylamines in mammalian species. These enzymes are known
to be capable of activating arylamines to mutagenic species, or
rendering them biologically inactive. An obligatory step in the
metabolic pathway usually involves N—oxidation catalyzed by microsomal
monooxygenases cytochrome P—450, to form N—hydroxyaryIamines and
N—hydroxyarylamides (hydroxamic acids) (Frederick et al., 1982).
Cytochrome P—450—dependent N—hydroxylation of arylamines has been
demonstrated -In tissues of different mammalian species, including rabbit
bladder (Vanderslice et al., 1983). The relatively high capacity of
hamster liver tissue to activate arylamines and nitroso compounds to
derivatives mutagenic In Salmonella mutagenesis assays (Raineri et al,
1981; Phillips and loannides, 1984) also suggest the presence of high
levels of cytochrome P—450 activities in the liver tissue of hamsters.
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Alternatively, arylamines and hydroxamic acids can readily be
interconverted by N—acetyltransferase and deacetylase enzymes (King and
Glowinski, 1983). The N—hydroxy metabolites are proximate carcinogens
which can undergo further enzymatic processing, or undergo acid—
catalyzed reactions to ultimate carcinogens, usually defined by their
electrophilic reactivity with nucleic acids and protein (Miller and
Miller, 1981a; King and Glowinski, 1983). The proximate and ultimate
carcinogens are more carcinogenic than their parent compounds. Further
enzyme—catalyzed conversions that are known to occur involve conjugation
with sulfuric, acetic or glucuronic acids. Sulfate conjugation is
catalyzed by 3 ‘—phosphoadenosi rie—5 ‘—phosphosulfate (PAPS)—dependent
sulfotransferase and yields N—sulfonyloxyarylamides (Debaun et al., 1968
and 1970; Kadlubar and Beland, 1985), of a nitroxyl radical (Malejka—
Giganti et al., 1983). Enzyme—catalyzed sulfate conjugation with N—
hydroxyarylamine has been demonstrated (Lal et al., 1985). Sulfate
conjugation of N—hydroxyarylamides has not been detected in rat
extrahepatic organs (Irving et al., 1971; Garner et al., 1984), but the
reaction has been suggested to be responsible for activating N—hydroxy
metabolites of arylamines or arylamides, and, consequently, enhancing
hepatocarcinogenesis in the rat (Garner et al., 1984). N—hydroxy—
arylamines also readily form glucuronide conjugates which are
k~illi~h~ hi
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unreactive and stable at neutral pH. The N—hydroxyarylamine—
glucuronides are formed in the liver, enter the circulation, from where
they are readily transported to the lumen of the urinary bladder..
Transport to the intestine is believed to occur by excretion through the
bile duct. In the bladder, they are hydrolyzed to the free carcinogenic
N—hydroxy—arylamines through protonation under the mildly acidic pH of
urine (Kadlubar et al., 1981) or reacted upon by beta—glucuronidases in
the intestine (Kadlubar et al., 1977). The effect of pH has been
demonstrated in a study showing that the relative amounts of free and
conjugated N—hydroxy—2—naphthylamine excreted in normal urine of rats
(pH 6.7) given BNA is altered by changing urinary pH with administered
NaH2003 or NH4C1 (Kadlubar et al., 1981). The resulting N—hydroxy
aglycones are directly mutagenic, react spontaneously with nucleic acids
and protein, as well as inducing tumors at sites of application in
experimental animals (Kadlubar et al., 1981; Oglesby et al., 1981).
Enzymatic N—acetyltransfer is encountered at least twice in the
metabolic pathway of arylamines. There is an acetyl—CoA—dependent
transfer of acetyl group unto primary amines in arylamines, or intra
molecular acetyl transfer of hydroxamic acid from the amine nitrogen to
the oxygen attached to this nitrogen, which is an AcC0A—independent
arylhydroxamic acid—mediated N,O acetyl transfer (reviewed in Weber,
hi
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1987 and Hem, 1988b). The AcCoA—dependent acetylation reaction appears
to be a deactivation reaction, converting arylamines to non—reactive
species which are excreted in urine or feces. The N,O—acetyltransfer
reaction, catalyzed by N,O—acetyl—transferase (N,O—AT), yields
acetoxyarylamine intermediates that breakdown to arylnitrenium ions with
loss of the acetyl group, followed by covalent binding of the
arylnitreriium ions to DNA (Flamang and Kadlubar, 1985). The N,O—AT
activity appears to be an activating reaction which plays an important
role in certain arylamine—induced carcinogenesis. Rat mammary gland,
for example, has N,O—AT activity but non—detectable N—OH—AAF deacetylase
or sulfotransferase activities (Irving et al., 1971). This tissue has
been reported to readily develop tumors following a single application
of N—OH—AAF (Malejka—Giganti et al., 1973 and 1977). However, the
relationships of N,O—AT activity to other acetyltransferase activities
are still not completely understood.
The generation of 0—acetyihydroxylamines from N—hydroxyarylamInes,
catalyzed by an acetyl CoA—dependent 0—acetyltransferase has also been
proposed as an important step in the metabolic activation of arylamines
(Flammang et al., 1985). Catalytic 0—acetylation activity has been
separated into two isozymes in hamster liver (Hem et al., 1987c) and
the activity co—elutes with partially purified NAT isozymic fractions
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derived from hamster liver cytosol (Trinidad et al., 1989) and mouse
liver cytosol (Mattano et al., 1988).
N—deacetylatlon of N—hydroxyacetylarylamines to their respective
N—hydroxyarylamjne and acetyl derivatives has also been determined, in
various organs of experimental animals Including, hamster, mouse, rat,
guinea pig and rabbit (Irving et al., 1966 and 1979), as well as in dog
and human urothellal tissues (Wang, 1985). Two forms of hepatic
microsomal N—OH—AAF deacetylase activities have been identified In
guinea pig (Glowinskl et al., 1983), both of which are inhibited by
paraoxon. This susceptibility to paraoxon serves to distinguish them
from cytosolic NATs which are resistant to paraoxon (King and Glowinskl,
1983). The deacetylase activity has been suggested to play an important
role in the metabolic activation of N—OH—AAF to generate arylamlne—DNA
adducts, as well as, mutayens positive in the Salmonella test system
(Aune et al., 1985).
Alternatively, ring—oxidation and peroxidative reactions have been
proposed as metabolic pathways for arylamines. Ring oxidation IS
generally considered a detoxification reaction, but, an electrophiljc
iminoquinone can be formed by a secondary oxidation of aminophenol
metabolite (Yamazoe, 1984). Peroxidase—cataJyzed reactions that involve
free radical intermediates have been identified in the formation of
aIiI~ ,IIidid~
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reactive imines from primary arylaminas (Josephy, 1983). The oxidation
of arylamines by the peroxidase activity of prostaglandin H synthase
(PHS) has been studied extensively (Kadlubar at al., 1982; Eling at al.,
1983; Zenser et al., 1983; Boyd and Eling, 1985). The specific reaction
involves the reduction of hydroxy—peroxides to alcohols through two
sequential one—electron steps leading to the formation of free radical
products from the electron donor species, such as arylamines (Boyd at
al., 1983; Boyd and Eling, 1984). The free radical derivatives
generated are thought to represent activated electrophilic forms of
arylamine carcinogens. It has been hypothesized that PHS may serve as
an alternative activating system in arylamine—induced bladder
carcinogenesis (Zenser at al., 1983). This hypothesis is supported by
studies showing PHS—catalyzed binding of several arylamines to nucleic
acid ~ vitro to form DNA adducts (Kadlubar at al., 1982; Morton at al.,
1983; Krauss and Eling, 4985). This reaction has also been associated
with the mutagenic activation of AF in the Ames Salmonella assay (Boyd
et al., 1985). There is evidence of relatively high PHS activity
detected in the dog urothelium, but little or no cytochrome P—450
activity was detected (Wise et al., 1984). It has been suggested that
urinary bladder transitional epithelium is more susceptible to
peroxidase—mediated chemical carcinogenesis than the non—transitional
tissue, due to cooxidative activation of chemical carcinogens by
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prostaglandin H synthase occurring at a high level in the epithelium,
but only minimally in the non—transitional bladder tissue (Mohandas et
al., 1984).
Bio1o~ical Significance of the Acetvlation Reaction
The N—acetylation reaction is recognized as an important step in
the biotransformation of various arylamine drugs Including PABA and PAS
(Weber, 1973). It is also important in the metabolism of several
arylamine carcinogens including AF, ABP, BNA and benzidine (Glowinski et
al., 1978). Recent studies have demonstrated AcC0A—dependent and
N—OH—AAF—dependent N—acetyltransfer in the heterocyclic arylamine food
mutagen Trp—P—2, by rabbit liver cytosol enzyme, as well as, Trp—P—1,
Glu—P—1 and 10, by mouse liver cytosol enzyme (Shinohara et al., 1984).
These enzymatic reactions are catalyzed by AcCoA—dependent NAT enzymes,
thought to be expressed primarily in liver and gut mucosa (Weber , 1973;
Weber and Hem, 1985), but also, in lower levels in other tissues
Including peripheral blood, intestine, lung, kidney and the bladder.
The N—acetylation reaction proceeds through a two—step process, referred
to as a ping—pong bi—bi reaction mechanism. The cofactor AcC0A binds to
the enzyme and is released .before the arylamine substrate, with acceptor
amine, enters the reaction, to form the acetylated enzyme/substrate
intermediate.
.bII~~ HIlkd~i h I
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AcC0A C0A Acceptor amine Acetylamine
4. t
NAT AcNAT NAT
•AcC0A + NAT <—> C0A + AcNAT
Ac—NAT + Amine <—> Acetylamine + NAT
Transfer of the acetyl group from the acetylated enzyme Intermediate to
the acceptor amine then follows (Bessman and Lipmann, 1953; Jenne and
Boyer, 1962; Cleland, 1963; Andre et al., 1985).
The first clinical significance of the acetylation reaction to be
recognized involved its association with the elimination of INH,
following therapeutic dosing for the treatment of tuberculosis (Hughes,
1953). Shortly thereafter, it was also observed that toxicity to the
drug was developed in some patients, and that susceptibility to toxicity
could be attributed to differences in the capacity to acetylate the drug
(Hughes et al., 1954). Further studies have since confirmed that the
acetylation capacity exhibits a well—defined genetic variation in humans
(Evans et al., 1960 and 1964) and several other mammalian species
including, rabbits (Frymoyer and Jacox, 1963; Glowinski et al., 1978),
mouse (Tannen and Weber, 1980; Glowinski et al., 1981) and hamster
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(Hem et al., 1982). The mode of inheritance follows simple autosomal
Mendelian genetics of two codominant alleles. Studies carried out in
human (Evans et al., 1960; Okinaka et al., 1961) and animal models have
been consistent with a trimodal distribution of N—acetylation capacity
(Weber, 1987; Hem et al., 1985). Individuals can be classified as
homozygous rapid acetylators, heterozygous acetylators, or homozygous
slow acetylators, with hi9h, intermediate and low hepatic NAT
activities, respectively. Slow acetylators are homozygous for the slow
acetylator allele while rapid acetylators are homozygous for the rapid
acetylator allele (Hem, 1988).
N—Acetylption Polymorphism in the Inbred Hamster Model
The NAT activity in liver cytosols of hamsters, guinea pigs, mice
and rats have been assessed (Lower and Bryan, 1973; Hem et al., 1982;
reviewed in Weber , 1987). Generally NAT activity for arylamine
substrates in these species was in the order AF > ABP > BNA, while the
capacity for enzyme activity in each species was In the order hamster
(18—fold) > guinea pig (12—fold) > mouse (8—fold) > rat (1—fold). The
hamster expresses 9— to 10—fold higher activity than a human rapid
acetylator and 120—fold greater activity than a human slow acetylator
(Lower and Bryan, 1973). The rat is intermediate to both the human slow
and rapid acetylators (reviewed in Weber, 1987).
t~ 0
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The acetylation polymorphism in the hamster was discovered after
similar observations in the mouse and rabbit (Hem et al, 1982).
Surveys of hepatic cytosolic NAT activities in several inbred hamster
strains have identified the Blo. 87.20 strain as the prototype rapid
acetylator and the Bio. 82.73/H as the prototype slow acet.ylator (Hem
et al., 1982 and 1985). The expression of NAT activity in extrahepatic
tissues such as kidney, intestine, lung and bladder has also been
determined to be acetylator genotype—dependent, concordant with hepatic
activities (Hem et al., 1987a and 1987b). The polymorphic expression
of liver and bladder aryl.amine NAT activity is of interest because of
the reported higher incidence of arylamine—induced bladder cancer among
human slow acetylators. A proposed molecular mechanism for this
genotype—dependent predisposition to cancer implicates individual
differences in the capacity for NAT activity. It is suggested that high
levels of N—acetylation of arylamines competes with the arylamine
oxidation reaction, essentially reducing the levels of activated
metabolites reactive with bladder tissue DNA. Although the liver is
recognized as the primary site for the metabolism of arylamines, It is
thought that the bladder may also play some role, through acid
hydrolysis or enzyme—catalyzed reactions localized In the epithelium.
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This hypothesis is supported by studies which have demonstrated the
capacity of bladder epithellum for metabolic activation of arylamines to
genotoxic products (Kadlubar et al., 1982; Vandersilce et al., 1983;
Wise et al., 1984), as well as, the expression of NAT activity (Hem et
al., 1987b). It has been suggested that N—acetylatlon is a
detoxification reaction during the biotransformation of arylamine
leading to bladder carcinogenesis (Lower and Bryan, 1973; Radomski,
1979).
Comparative studies of enzyme—catalyzed acetyl transfer reactions
in hamster tissues show relatively high and polymorphic NAT activity,
towards arylamines in the liver, kidney, intestine, lung and bladder
(Hem et al., 1987a and 1987b). The AAF deacetylase, N—OH—AAF
deacetylase and N—OH—AAF transacetylase activities determined were
acetylator genotype—independent and were non—detectable In the bladder
tissue (Hem et al., 1986). The presence of relatively high and
polymorphic expression of N—hydroxyarylamine OAT has been reported in
the liver, kidney and lung tissues of hamsters, but not In the bladder
(Hem, 1988; Hem et al., 1987a). The OAT activity is thought to be
involved In metabolic activation of colonic arylamine carcinogens
(Flammang et al., 1985).
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The acetylator status provides valuable information in the
assessment of therapeutic, pharmacological and toxicological profiles of
unusual susceptibility to drugs, environmental as well as industrial
pollutants. In addition to the acetylator genotype—dependent expression
of NAT activity, two isozymes of the enzyme have been isolated from
hamster liver cytosol by ion—exchange chromatography on DEAE—cellulose
(Hem et al., 1985; Trinidad et al., 1989). Although the importance of
structural variance of NATs is still under investigation, genetic
variability in acetylation capacity has significant implications in
individual pre—disposltlon to drug—induced toxicities, spontaneous
disorders and especially, various forms of cancer (reviewed in Weber,
1987).
N—Acetylation Polymorphism and Arylamine—Induced Carcinogenesis
The role of NAT activity in the detoxification of carcinogenic
arylamines metabolized from N—substituted aryl compounds has been
evaluated In experimental animals as well as man (Lower and Bryan, 1973
and 1976; Lower et al., 1979; Weber et al., 1988; McQueen et al., 1987).
Initial observations have shown that the ultimate carcinogenic
metabolites of arylamines involved in bladder carcinogenesis are non—
acetylated (Lower and Bryan, 1976). An animal model used earlier in
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elucidating the mechanisms of arylamine—induced bladder carcinogenesis
was the dog, which has a deficiency for N—acetylation, but has the
capacity for deacetylase activity. In addition, the dog urothelium has
little or no detectable cytochrome P—450 activity (Wise et al., 1984)
and thus, probably, uses PHS as an alternative activating system during
arylamine—induced carcinogenesis (Boyd and Eling, 1985). The
administration of several arylamine carcinogens to dogs has been
observed to induce only urinary bladder tumors, thus, it was concluded
that N—acetylation is not required for urinary bladder carcinogenesis,
since this enzyme activity is absent in dogs. In contrast,
administration of structurally analogous carcinogenic arylacetamides to
dogs produced both bladder and liver cancer, giving further evidence
that removal of the acetyl group Is required for bladder carcinogenesis
(Lower and Bryan, 1976). A relationship between NAT phenotypes, and
human bladder cancer was first reported by Lower et al.,(1979). In a
survey conducted by Hanssen and coworkers (1985), the slow acetylator
human phenotypes showed a significantly higher incidence of bladder
cancer than a healthy control group. Several other investigators
studying occupational exposure, cultural habits and the stage of
arylamine—induced cancer also observed a similar association between
bladder carcinogenesis and acetylator status (Cartwright et al., 1982;
Evans et al., 1983; Miller and Cosgiff, 1983).
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Recent studies have examined the distribution of rapid and slow
acetylator phenotypes In patients with colorectal carcinoma and age—
matched controls. A significantly higher frequency of rapid acetylators
was observed in colorectal cancer patients compared to healthy controls
(Lang et al., 1986; tlett et al., 1987). ThIs finding contrasts very
strikingly with the higher frequency of bladder cancer in slow
acetylators, but is consistent with the hypothesis that high levels of
NAT activity present in human colonic mucosa Is paralleled by high
levels of 0—acetylation of N—hydroxyarylamines, seemingly catalyzed by
the same enzyme. Thus, it is thought that 0—acetylation leads to the
generation of electrophilic metabolites which bind to colon DNA (Westra
et al., 1985; Flammang et al.., 1985).
An analysis of data from studies on the relationship between
acetylator status and breast cancer suggests a significantly greater
relative risk, about 2.05—fold, for rapid acetylator , compared to slow
acetylator individuals (Evans, 1986). A large excess of rapid
acetylators, about 68%, was observed In a group of Russian patients with
Invasive breast cancer, compared to slow acetylators, comprising about
32% (Bulovskaya et al., 1978). When compared to corresponding age—
matched control groups, however, the levels of acetylating capacity in
the cancer patients were relatively higher. In another study by
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Cartwright (1984), in London, it was Initially reported that a greater
frequency of rapid acetylators was observed in patients with benign
breast cancer compared to a healthy control group. In the same study,
the frequency of rapid acetylators in patients with malignant breast
cancer did not, however, differ remarkably from the healthy control
group. Subsequent studies could not establish this same relationship.
The possible role of acetylator status on the development of breast
cancer is still not clear, due to conflicting epidemiological reports
presently available.
Test Systems for Evaluating Arviamine—Induced Genotoxlcitv
The implication of various arylamines as causal agents In the
etiology of cancer in different human tissues , as well as experimental
animals, is well documented. The discovery of the capacity of
metabolically activated carcinogenic arylamine derivatives to covalently
bind cellular macromolecules of susceptible tissues, provided the first
picture of a cellular event in the initial process of carcinogenesis
(Miller, 1952). Several lines of evidence implicate DNA damage in the
process of chemical carcinogenesls, and It is now known that most agents
which cause cancer also damage DNA (reviewed in Setlow, 1982).
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The transformation of a normal cell to a cancerous state by exogenous
carcinogenic arylamines is now generally recognized as a highly complex,
multifactorial process caused, in part, by endogenous metabolic factors
and, in part, by pertubations In the cellular DNA structure. The
activity of the mammalian enzymes that catalyze the metabolism of
xenoblot.lcs is an important endogenous factor that influences the
concentration of reactive metabolites In target cells and organs and,
consequently, the magnitude of adverse biological effects. Perturbation
of DNA structure, on the other hand, is thought to induce heritable
genetic lesions such as mutation and/or chromosomal aberrations, or
changes in chromosome numbers (Sorsa, 1980) which, under appropriate
conditions, can allow a cell to escape the growth control of the
organism and become a neoplasm (Tabin et al., 1982; Beland at al.,
1983). There Is still less certainty, however, about the reactions that
intervene between DNA binding and cellular transformation. Experimental
approaches used in elucidating the critical events In chemical
carcinogenesis utilize knowledge of underlying biological, molecular,
biochemical and cellular mechanisms. As a result, many different assay
techniques have been developed and are utilized in assessing the geno—
toxic capacities of arylamines (reviewed in IARC, 1980; Larsen at al.,
1982), as well as extrapolating data to predict cancer risk to humans.
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Assay techniques have been developed that enable the measurement of
direct and indirect DNA damage In situ; typically, genetic lesions in
the form of specific locus—gene mutation and chromosomal aberrations
induced In prokaryotic or eukaryotic cell systems (Chu and Malling,
1968; Zimmerman, 1973; Ames et al., 1973; Bignami et al., 1974; McCann
and Ames, 1976; Vogel and Sobel, 1976; Parry and Zimmerman, 1976; Kuroki
et al., 1977; Ishidate and Odlshima, 1977; Hsie et al, 1979; Mutsuoka
et al., 1979; Mohn et al., 1980), induction of DNA adducts (Miller and
Miller, 1971; Moore and Koreeda, 1976; Baird, 1979; Gupta et al., 1980;
Beland et al., 1983) or breakage (McGrath and William, 1966; Lett et
al., 1967; Kohn and Ewig, 1973; Swenberg et al., 1976); and the cellular
responses, such as stimulation of DNA repair (Slater et al., 1971; Kada
et al., 1977; Mohn et al.,, 1983), somatic recombination between
homologous or sister chromatids (sister chromatid exchange (SCE))
(Taylor, 1958; Perry, 1980; Stetka, 1979), or unscheduled DNA synthesis
(UDS)(Rasmussen and Painter, 1964; Evans and Norma, 1968; Stich and.San,
1970; Williams, 1976, 1977 and 1980), produced during this repair.
Radioactive carcinogens have provided most of the present knowledge
of interactions between arylamine carcinogens and biological systems
(Moore and Koreeda, 1976; Baird, 1979; Singer and Grumberger, 1983;
Beland et al., 1983). This approach examines the interaction of
IIIi~~~ II
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arylamines at a gross level, that is, the total binding of arylamine to
cellular macromolecules. Target cells jj~ vivo or ~ vitro are exposed
to a radlolabeled arylamine, the DNA is extracted and total
radioactivity is measured by scintillation counting. The amount of
labeling is then expressed as a percentage of the total DNA, as
determined chemically. Although straightforward, this approach Is
subject to errors, including for instance, non—specific binding of
carcinogens to RNA and protein (Miller and Miller, 1977) which often
contaminate DNA preparations, or loss of radiolabel from test chemical,
either spontaneously or during repair. Another major limitation of this
assay system is the restricted number and quantity of radioactive
carcinogens that are readily available in isotopically labeled form.
However, to extend the scope of carcinogen—DNA binding studies,
alternative methods which do not rely on radiolabeled carcinogens have
been developed. Two new and widely used assay systems are the
Immunoassay technique (Poirier et al., 1977 and 1980; Hsu et al., 1981),
and the [32P]—postlabellng TLC or HPLC technique (Randerath, 1981; Gupta
and Randerath, 1982; Haseltine et al., 1983; Levy and Weber, 1988).
Immunoassays are designed to determine the concentration of an unknown,
unlabeled adduct, by comparing its Inhibitory effect, on the binding of
a known labeled adduct, to a specific antibody. This is then compared
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with the inhibitory effect of known standard adducts. This assay system
is sensitive in detecting very small amounts of adducts, In the
femtomole range, but is limited by the specific activity of the agents,
including radioisotope or enzymes, used in localizing ligand—bound
antibodies. On the other hand, the basic procedure of the [32P]—post—
labeling technique invol~ies incorporating highly specific [32P] Into non—
radioactive nucleic acid constituents by enzyme—catalyzed
derivatization, followed by chromatographic separation of radioactive
products. This assay technique has found the wider application in DNA—
binding assays for chemical carcinogenesis studies, due to its high
sensitivity also in the ~emtomole range, specificity and consistency.
The chemistry of biological interactions cannot be used alone to
define the complex events of carcinogenesis, especially since not all
such Interactions are genotoxic endpoints nor result In neoplasia.
There are, however, numerous reports showing a high empirical
correlation between genotoxicity measured in prokaryotic or eukaryotic
cell systems and carcinogenicity In higher organisms (Leifer et al.,
1981; Beland et al., 1985; Swenberg et al., 1985).
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Relationshios Between DNA Adduct Formation and Arylamine—Induced
Bladder Carc1no~enesis
The relationships between chemical carcinogenesis and DNA adduct
formation have been investigated for numerous arylamines. There Is much
circumstantial evidence that DNA Is a critical target in carcinogenesis
and the ultimate forms of most carcinogens, Including arylamines, are
electrophiles which readily interact with DNA (Miller and Miller, 1976;
Miller, 1978). The covalent binding of arylamine carcinogens with DNA
Is widely believed to be a critical step In the initiation of
carcinogenesis. Arylamine—nucleic acid adduct formation results
directly from the spontaneous coupling of a carbonium ion formed from
the acetoxyarylamine and nucleic acid (Kriek, 1965; Kadlubar et al.,
1977; Beland et al., 1979). It has been proposed that the generation of
reactive metabolites In the bladder Involves the N—hydroxylatlon of the
carcinogen in the liver, followed by N—glucuronidation. The glucuronide
conjugate is transported to the bladder lumen where under the slightly
acidic environment of urine, the glucuronide conjugate is hydrolyzed to
release the electrophilic N—hydroxy species, which then binds to bladder
DNA. N—acetylation has been proposed as a detoxification pathway for
bladder carcinogenesis induced by arylamlnes, through competition with
the N—hydroxylatlon reaction and essentially reducing the levels of
activated electrophiles to which the bladder is eventually exposed.
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This suggestion is supported by the observation that rat species which
readily N—acetylate arylamines are not susceptible to benzidine—induced
bladder cancer (Radomskl, 1979), while the dog which is unable to
N—acetylate benzidine and other arylamines, is susceptible to benzidine—
induced bladder cancer, but not liver cancer (Poirler et al., 1963;
Lower and Bryan, 1973; Poupko et al., 1983).
A wide variety of DNA—adducts formed by covalent attachment of
different activated arylamine derivatives have been identified. The
three major arylamine—DNA adduct species that have been identified,
mainly in the tissues of experimental animals include, N—[deoxyguanosjr,—
8—yl]—arylamjne (C8—dGuo—), N—[deoxyguanosin—8—y1]—acetylated_ary1~i~e,
and 3—[deoxyguanosin—N2—yl]—acetylated—aryl~jne (Kriek et al., 1969;
Beland et al,, 1979). The C8—dGuo—arylamine adduct has been determined
to constitute the major detectable species generated with arylamines.
It is the predominant species detected In dog bladder following exposure
to arylamines (Kadlubar and Beland, 1985). The arylamlne—DNA adducts
exhibit a broad spectrum of chemical stability and biological
persistence. Interaction products from various arylamine carcinogens
have been shown to persist for periods of several months after a single
dose and to accumulate in some cases (Warwick and Roberts, 1967; Beland
et al., 1983). The extent of interaction of chemical carcinogens with
35
DNA has been determined to correlate with carcinogenic potential
(Brookes and Lawley, 1964; Slaga et al., 1977). It has also been
determined that there is an association between arylamine—DNA adduct
levels and Jj~. vitro genotoxicity (Arce at al., 1987; Beland et al.,
1983), adduct levels and chromosomal damage CHef lich et al., 1985), as
well as with mammalian cell transformation (McCormick and Maher, 1983).
However, little is still known about the consequences that persistent
adducts have on DNA replication and gene transcription.
Inter—individual differences in the metabolism of arylamines is an
important factor in species and tissue specificity in the carcinogenic
effects of arylamines. The induction of bladder tumors by repeated
subcutaneous, intraperitoneal, intratracheal, or oral administration of
BNA and AAF has been documented (So and Wynder, 1972; Oyasu at al., 1972
and 1973; Saffioti et al., 1976). These human and animal species—
specific organotropic bladder carcinogens have been shown to be
N—hydroxylated to electrophiles that react spontaneously with nucleic
acids to form adducts with bladder DNA (Kadlubar at al., 1981). The pH
of urine and the voiding interval have been suggested to affect the
levels of electophilic metabolites generated in the bladder as well as
the duration of exposure of the urothelium to these activated
metabolites (Youn9 and Kadlubar, 1982; Kadlubar et al., 1987).
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In a previous study by Kadlubar and coworkers (1981), the relative
amounts of conjugated N—hydroxy—2—naphthylamine excreted in normal urine
(pH 6.7) of rats , given BNA was observed to be altered by changing
urinary pH with administered sodium bicarbonate or ammonium chloride.
In another j.j~ vitro experiment with BNA, 4—nitrobiphenyl and AAF, the
carcinogen—DNA adducts formed in dog urothellum, at pH 5.0, were found
to be identical to the products obtained by reaction of their N—hydroxy—
arylamines with DNA. In addition, the major and persistent BNA— and
ABP—DNA adducts were found to be C8—substituted deoxyguanosine (Kadlubar
et al., 1981 and 1982) and the biological persistence of C8—deoxy—
guanosine adducts has been shown to correlate with organ specificity
(Kadlubar et al., 1981).
In animal species such as dog, which have little or no cytochrome
P—450 activity in the bladder tissue, there is the requirement for
another activating system for arylamines to be carcinogenic. The PHS
system is recognized as an alternative pathway to the cytochrome P—450
activating system. In a comparative study, urinary bladder transitional
epithelium was observed to be more susceptible to peroxidase—mediated
chemical carcinogenesis, than urinary bladder non—transitional tissue
(Mohandas et al., 1984). High levels of PHS activity were detected in
the urinary bladder epithelium, and only minimal activity in the
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non—transitional tissue. Although these tissues are closely aligned,
the differences in PHS activity are thought to be responsible for their
differences in susceptibility to arylamine carcinogenesis.
The arylamine—DNA adduct species formed by the PHS system are
different from those formed by cytochrome P—450 system, due to the fact
that with the PHS system, arylamines are oxidized by one—electron
mechanism to free radical metabolites. A C—oxygenated metabolite and a
free radical species have been detected following PHS—catalyzed
activation of BNA (Kadlubar et al., 1982; Boyd and Eling, 1987). The
PHS—dependent formation of 2—lmlno—1—naphthoquinone—DNA adduct has been
demonstrated (Yamazoe et al., 1985). Other studies have also
demonstrated a PHS—catalyzed binding of several arylamine carcinogens,
including bladder specific arylamines, to nucleic acid jjj vitro (Morton
et al., 1983). Mono— and diacetylated—benzidines are known to be poor
substrates for PHS activation (Morton.et al., 1983), an observation
consistent with N—acetylation serving as a detoxication pathway in
aromatic amine bladder carcinogenesis.
Rationale
Enzyme—catalyzed N—acetylation is an important reaction in the
metabolic activation/deactivation of arylamine carcinogens. A genetic
polymorphism Is expressed by both man and hamster in their capacities to
acetylate chemical carcinogens, and slow acetylator human genotypes are
more frequently associated with the incidence of arylamine—induced
bladder carcinogenesis. Since N—acetylation appears to play a role in
the genetic pre—disposition to arylamine—induced bladder cancer,
variations in hepatic and bladder NAT activities may form a basis for
differences in susceptibility to arylamine—induced genotoxicities. This
tendency is likely to be reflected In the correlation of slow acetylator
phenotypes with reduced capacity to detoxify arylamines or their
activated derivatives, to non—genotoxic species and consequently,
greater incidence of arylamirie—induced genotoxicity.
The experimental approaches that were used in assessing this
rationale are listed under the section on ‘Aims of Research”.
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Aims of Research
The research aims of this project were:
1. To determine AcCoA—dependent arylamine NAT activity in cytosolic
preparations derived from hamster bladder, with respect to
acetyl ator genotype.
2. To characterize NAT activity in hamster bladder cytosol by partial
purification of NAT Isozymes and determination of pharmacokinetic
constants, Vmax and <rn, using various arylarnines as substrates.
3. To determine the levels of DNA—arylamine adducts induced In the
liver and bladder of hornozygous rapid and hornozygous slow
acetylator hamsters, following an acute treatment with arylamine.
4. To determine the relative capacity of hepatic S9 preparations
derived from hornozygous rapid and homozygous slow acetylator
hamsters for mutagenic activation of AF and the modulation of




Chemicals for Pharmacokinetic Assays
Reagent grade PABA (potassium salt), PAS (sodium salt), AcC0A
synthetase (EC 62.1.1), trypsin (EC 3.4.21.4), collagenase (3.4.24.3),
DMSO, DTT, EDTA, DAB, AF, ABP, and BNA were purchased from Sigma
Chemical Co., St. Louis, MO.; AcCoA (lithium salt) from Pharmacia Inc.,
3
Piscataway, NJ.; and [ H]—sodium acetate (4.5 Ci/nimol) from Dupont/New
England Nuclear Co., Boston, MA.
Chemicals for DNA Adduct Analysis
SDS, Tris—HC1, phenol, chloroform, sodium chloride (NaCl), sodium
citrate, magnesium chloride (MgCl2), L—glycerol--3—phosphate, lithium
chloride (Lid), lithium formate, sodium phosphate, lithium hydroxide,
sodium succinate, and calcium chloride (Cad2) were obtained from
Fisher Scientific, Houston, TX.; EDTA, RNase A (EC 3.1.27.5., Type lila,
75U/mg), RNase Ti (EC 3.1.27.1., Grade IV, 400 U/mg), Microccocal
endonuclease (EC 3.1.31.1., 74 U/mg), DTT, sodium adenosine diphosphate,




potato apyrase (EC 3.6.1.3., Grade 1,2 U/mg), urea, calf thymus DNA,
DMSO, ethanol, AF and ABP, were obtained from Sigma Chemical Co., St.
Louis, MO.; protelnase K (20 U/mg), calf spleen endonuclease
(phosphodiesterase, 1 U/mg), NAD (Grade I, 100%), glycerol—3—phosphate
dehydrogenase (EC 1.1.1.8., rabbit muscle, 100—250 U/mg), triose
phosphate i somerase (EC 5.3. 1 .1.), glyceraldehyde-3—phosphate
dehydrogenase (EC 1.2.1.12., rabbIt muscle, 80 — 120 U/mg),
3—phosphoglycerate kinase (EC 2.7.2.3., yeast, 500 U/mg), lactate
dehydrogenase (EC 1.1.1.27., rabbit muscle), polynucleotide kinase
(EC 2.7.1.78, T4 amN82—infected E coil B), were obtained from Boehrlnger—
Mannhelm Biochemicals, Indianapolis, IN.; [32P]H3P04 and [14C]—ink were
obtained from ICN Blochemicais, Irvine, CA.; formic acid was obtained
from Aldrich Chemical Co., Milwaukee, MN.; PEI—ceilulose thin layer
plastic—backed sheets were manufactured by Merck and purchased from
Alitech Inc., Waukeegan, IL. Sheets were pre—developed overnight with
distilled water before use, marked and stored at 20C.
All chemicals and AF— and ABP—DNA edduct standards used for the
DNA adduct studies were the generous gifts of Dr. Glenn Talaska, at the
Nationa.1 Center for Toxicological Research, Jefferson, AR.
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Chemicals for Salmonella Mutagenesis AssaYs
Bacto agar, Vogel—Bonner minimal glucose agar medium, KC1, MgCl2,
sodium dihydrogen phosphate, disodium hydrogen phosphate, NADP, glucose—
6—phosphate, D—glucose, D—biotin, L—histidine—HC1, were obtained from
Sigma Chemical Co, St. Louis, MI.
Bacteria
Histidine—requiring Salmonella tvøhimurium tester strain TA98 with
rfa mutation, uvrB mutation and containing the r—factor plasmid was used
for mutagenesis assays. This was a kind gift from Or. Robert Heflich at
the National Center for Toxicological Research, Jefferson, AR.
Animals
Homozygous rapid acetylator Bio. 87.20 inbred Syrian hamsters were
obtained from Bio Breeders, Watertown, MA.
Homozygous rapid acetylator MHA/SsLak inbred Syrian hamsters were
obtained from Charles River Laboratories Inc., Wilmington, MA.
Homozygous slow acetylator Bio. 82.73/H inbred Syrian hamsters
were originally supplied by the Blo Research Institute, Cambridge, MA.,
but are presently maintained at the Morehouse School of Medicine animal
care facility, Atlanta, GA.
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Heterozygous acetylator Blo. 87.20 x Blo. 82.73/H Syrian hamster
progenies were generated through appropriate crosses at the Morehouse
School of Medicine, Atlanta, GA.
Heterozygous acetylator MHA/SsLak x Blo. 82.73/H Syrian hamster
progenies were generated through appropriate matings at the Morehouse
School of Medicine, Atlanta, GA.
EQUIPMENTS
Mono Q HR 5/5 anion—exchange column used for FPLC was obtained from
Pharmacia Inc., Piscataway, NJ.
Motor—driven tissue homogenizer was from Biospec Products,
Bartlesville, OK.
Perkin—Elmer Lambda 3A spectrophotometer was from Perkin—Elmer Co.,
Norwalk, CT..
Fisher Acculite semi—automatic bacterial colony counter was




PreDaration Of Tissue Cvtosol for Pharmacokinatic Assays
Hamsters were anesthetized with carbon dioxide and decapitated.
The bladder and liver were carefully excised, followed by removal of
extraneous tissues. They were washed, minced and homogenized (25% w/v)
in ice—cold 20 mM potassium phosphate buffer, pH 7.4, 1 mM DTT and 1 mM
EDTA. Homogenization was carried out with a motor—driven homogenizer.
The homogenate was subjected to sequential centrifugation at 10,000 x g
for 20 mm followed by 105,000 X 9 for 60 mm. The supernatant
(cytosol) was isolated and assayed for total protein and NAT activity,
or further purified.
Isolation of Bladder Epithelial Cells
Bladder epithelial and epithelium—depleted (non—epithelial) tissues
were separated by a modification of the procedure described by Hix et
al. (1983). The hamsters were sacrificed as previously described and
the peritoneal cavity was opened to expose the bladder. The bladder was
washed twice by in3ecting phosphate—buffered saline, pH 7.4 and
carefully aspirating the contents of the lumen. The washed bladder was
filled with 02 to 0.5 ml of a trypsin/collagenase solution, surgically
tied at the urethral end with a string, and excised intact
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The intact bladder with fluid mix was placed in PBS for 60 mm at 4°C,
and then at room temperature for 30 mm. The bladder was subsequently
placed in a Petri dish containing 1 ml of fresh PBS, cut open to expose
the lumen, and carefully scraped with a pair of curved surgical forceps
to remove the epithelial layer. The tissue layer removed by this
procedure was observed under light microscopy and found to contain cells
with mainly polygonal morphology characteristic of epithelial cells in
primary culture. In addition, samples of the scraped cells were
0Incubated at 37 C and allowed to attach over a 24 h period, and little
or no contamination by fibroblast cells from the non—epithelial layer
was observed. The remaining epithellum—depleted tissue was placed in
PBS at 4°C. Each tissue was homogenized separately and centrifuged as
previously described, to isolate tissue cytosol.
Protein Determinations
Total protein in tissue fractions was quantified by the Bio—Rad dye
binding method of Bradford (1976).
~IIi~,h h
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Partial Purification of Bladder NAT Activity
Bladder cytosolic fractions derived from slow, rapid and
intermediate acetylator hamsters were partially purified by
anion—exchange fast protein liquid chromatography (FPLC). Cytosolic
protein (10 to 20 mg) was applied to an anion—exchange column
(1.6 x 4 cm Mono 0 HR 5/5). The column was equilibrated with filtered
and degassed 20 mM potassium phosphate buffer pH 7.4, 1 mM DTT and 1 mM
EDTA (start buffer). The elution buffer was made of filtered and
degassed 20 mM potassium phosphate buffer pH 7.4, 1 mM DTT, 1 mM EDTA
and 1 M KC1. The chromatography apparatus was programmed to an elution
flow rate of 1 mi/mm, beginning with a linear gradient from 0 to 120 mM
KC1, followed by a 10 ml isocratic elution, and finished with a linear
gradient. All enzyme isolation and purification steps were performed at
40C and the 1 ml fractions collected were used for protein
determinations as well as NAT activity assays.
Determination of AcCoA—DeDendent PABA and PAS NAT ActivitY
This assay was carried out using the procedure described by Hem et
al. (1982). Assays were conducted at 370C, using cytosolic or FPLC
fractions whose protein concentrations were pre—determined, and at time
periods of linear expression of enzyme activity, but not exceeding
L~III~~d~ I
47
80 mm. In Instances where activities were not completely linear,
initial velocities were determined by extrapolation of the time—activity
curve to the addition of AcC0A (time zero) and measuring the slope of
the tangent. The reaction mix was made of 0.22 mM substrate, 0.5 ml
enzyme fraction and 2.2 mM AcC0A, mixed In this sequence in a total
volume of 0.09 ml. In control tubes, water was substituted for AcCoA
Assays were carried out in duplicate and terminated with 10% acetic acid
at multiple time points not exceeding 60 mm. The AcCoA—dependent
disappearance of the arylamine substrate which is reflected by
decreasing Schiff’s base formation with DAB was then measured with a
Perkin—Elmer Lambda 3A spectrophotometer. The Absorbance at 460 nm was
determined using an ethanol blank.
Determination of AcCoA—Deiendent AF ABP and BNA
N—Acetyltransferase Activities
This assay was carried out using a modification of the method of
Andres et al. (1985), which measures AcCoA—dependent formation of
radiolabeled arylamide products. Initial concentration in the reaction
mixture was 0.5 mM arylamine substrate, 2.0 mM AcC0A and 0.06 ml of
suitably diluted enzyme fraction. The reaction was started by adding
0.02 ml of [3H]—AcC0A working solution containing [3H]—acetate (Sp. Act.
45 Ci/mmol). The reaction was terminated by adding a buffer
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made of 0.02 ml of 5 N NaOH, 100 mM sodium acetate, which hydrolyzes any
remaining [3H]—AcCoA to [3H]—acetate. In experiments to characterize
kinetic constants, appropriate substrate concentrations were used. The
[3H]—arylamide product generated in the reaction was then recovered by a
single extraction with 1.5 ml chloroform. The chloroform extract was
washed twice with water, and a 0.55 ml aliquot of the organic layer was
transferred to mini scintillation vials, evaporated to dryness,
redissolved in 0.3 ml DMSO, and the radioactivity recovered was counted
with a Beckman LS5801 liquid scintillation counter, after the addition
of scintillation cocktail. Control tubes received 0.2 ml of 25% DMSO
rather than AF. All assays were carried out In duplicate and enzyme
activity was calculated, using the formula;
(std DPM — Blank DPM)
3 x (Sample DPM—Blank DPM) x 245 nanomoles
Sp. Act.
(Minutes of Assay) x (mg of Protein)
Determination of Apparent Km and Vmax
Michaelis—Menten kinetic constants were determined for PABA NAT
activity in bladder cytosol by Eadie—Hofstee analysis. For
determinations of PABA apparent Kin, NAT assays were carried out with
PABA concentrations ranging from 50 to 500 micromolar in rapid
.!I
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acetylator cytosol and from 150 to 1000 UN in slow acetylator cytosol,
in the presence of 2.22 mM AcCoA. For determination of AcC0A apparent
Km, NAT assays were carried out with AcC0A concentrations ranging from
100 to 2250 UN in the presence of 2.22 mM PABA. The AcCoA apparent Km
was determined by NAT assays carried out with AcCoA concetrations
ranging from 100 to 2250 UN in the presence of 0.22 mM PABA.
Mlchaelis—Menten kinetic constants determination for AF NAT
activity In bladder cytosol as well as partially purified fractions were
carried out with AF concentrations ranging from 2 UN to 5 mM in the
presence of 2 mM AcC0A.
Data Analysis
Levels of NAT activity between acetylator genotypes were compared
by the Neuman—Keuls multiple range test. Michaelis—Menten kinetic
constants Km and Vmax were determined for AF NAT activity by ENZFITTER
non—linear regression data analysis (Leatherbarrow, 1987) and linear
regression of Eadie—Hofstee plots. The apparent Km and Vmax, determined
for NAT activity in enzyme fractions of slow and rapid acetylator
hamster bladder tissues, were compared by an one—way analysis of
variance, to test for differences. Data showing differences were
further analyzed by Neuman—Keuls multiple range tests to assess. the
levels of significance.
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Administration of AF or ABP to Hamsters for in vivo Arviamine
Genotox I citY AssaY
A working solution of AF and ABP were prepared separately at
30 mg/mi In DMSO. Hamsters were weighed and injected with 2 mi/kg
yielding 60 mg arylamine per kg body weight of the hamster. The
aryiamine solution was injected Into the peritoneal cavity with a
syringe needle. Treated animals were then put into an animal cage and
placed under a fume hood for 3 h or 18 h
Isolation of DNA
DNA was isolated from the liver and bladder tissues of slow and
rapid acetylator hamsters by a rapid solvent—extraction procedure
described by Gupta et al. (1984). This Involved homogenizing about 1 mg
of tissue in 0.024 ml of 1 M Tris—HC1 pH 7.4, 1 ml of 1% SDS—1 mM EDTA,
with a motor—driven homogenizer. The homogenate was then mixed with
0.024 ml RNase A (750 U/mi), followed by 0.08 ml RNase T1 (12.5 kU/mi).
The mixture was Incubated for 30 mm in a dry oven at 370C. The
homogenate was further treated with 0.06 ml proteinase K (200 U/mi) and
incubated for 30 mm at 37°C. This was followed by sequential
extraction of DNA with SDS/EDTA—saturated phenol, phenol/chloroform!—
isoamyl alcohol (25:24:1) and chioroform/Isoamyl alcohol (24:1).
~,hIhI L,!!!I.,,! - ~ ~
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Each extraction step was followed by centrifugatlon at 10,000 x g for 15
mm to separate the organic layer, which was discarded. Then, 1 ml of 5
ti NaC1 solution was added to the aqueous mixture and gently mixed. This
was followed by adding 100% cold ethanol (1:1 v/v) to precipitate DNA.
The DNA precipitate was pelleted. by centrifugatlon. The supernatant was
then discarded and the DNA pellet allowed to air dry. DNA was then re—
dissolved in succinate buffer (1.5 mM NaCl, 0.1 mM sodium citrate). The
amount of DNA extracted was estimated spectrophotometrically using a.
conversion factor of 20 A units per milligram of DNA. Recoveries260nm
averaged about 4 mg/g liver tissue and 1 mg/g bladder tissue.
Hydrolysis of DNA
DNA extracted from tissues of arylamine treated or untreated
hamsters were hydrolyzed to deoxynucleoside 3’—~onophosphates with an
hydrolysis mix containing. succinate buffer (10 mM CaC12, 20 mM sodium
succinate) pH 6.0, 2.5 ug spleen- phosphodiesterase (0.25 U/mI), 0.25 U
microccocal nuclease (25 U/mi), in a total volume of 10 ul, at 37°C, for





A modification of the procedure of Johnson and Walseth (1979) was
used for synthesizing radiolabeled ATP for labeling sample nucleotides.
Synthesis was achieved by the transfer of radioactive phosphorus from
[32P]1,3—diphospho—giycerate to ADP as part of a four—step enzymatic
conversion of L—glycerol—3—phosphate to 3—phosphoglycerate.
Standard Labeling of Nucleotides with Excess ATP
The conditions of excess ATP used for labeling nucleosides were
previously described by Gupta et al., (1982). Each aliquot (4.4 ul) of
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diluted hydrolyzed DNA sample was incubated for 40 mm at 37 C, with
6.6 ul of a labeling mixture containing 250 uCi [32P]ATP, 0.6 mM ATP
(cold), 1.8 U polynucleotide kinase, 0.1 M bicine and 1.0 ul
polynucleotide kinase buffer mix (20 mM bicine—NaOH pH 9.6, 10 mM OTT,
10 mM MgCl2, 1 M spermidine), pH 9.6. Under this condition, nucleotides
were limiting and were labeled to completion. Excess ATP present at the




Resolution of [32P]—Postlabeled Nucleotide Adducts
The procedure described by Lai et al. (1987) was used, with some
modifications, to isolate major DNA adducts in tissues of arylamine
treated hamsters. A 16 ul aliquot of each post—labeled sample was
spotted at separate origins 14 cm from the bottom of a 20 x 20 cm PEI—
cellulose plate. Each assay run had 3 — 4 samples spotted in
duplicate. Each run also had a standard DNA sample that had been
pre—adducted with AF or ABP, as well as DNA derived from hamster that
had been treated with vehicle only to serve as positive and negative
controls, respectively. The controls were spotted on each side of the
plate while the experimental samples were spotted in the middle. A
Whatman *1 wick was stapled to the bottom of the plate and placed in a
closed vessel containing 0.8 K sodium phosphate buffer pH 6.8 (Dl), with
the wick protuding out of the vessel. The chromatogram was developed
overnight, the wick was then cut off and carefully discarded. The
remaining chromatogram was washed twice by rinsing in distilled water
and air dried. The chroniatogram was then subjected to a second
resolution, which was in a direction 1800 opposite the Dl resolution, in
a buffer made up of 7 N urea and 3 K lithium formate, pH 3.5 (D2). This
was developed to the top of the chromatogram and then washed twice again
by rinsing in distilled water. The chromatogram was air—dried and cut
lL~~ I
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horizontally about 2 cm above the origin where the samples had been
spotted. The small piece of chromatogram containing the origins was
carefully discarded and the remaining chromatogram was re—developed to
the top, with a buffer made up of 6.8 14 urea, 0.65 14 L1C1 and 0.4 14 TrIs—
HC1 pH 8.0 (D3), in the same direction as the 02 resolution. The
chromatogram was washed twice by rinsing in distilled water and a fresh
wick attached to the top. It was then developed again to the top with a
0.8 14 sodium phosphate buffer pH 6.8 (04), to clean—up the chromatogram
and reduce background radioactivity on it. The wick was cut off and
carefully discarded. The remaining chromatogram was air dried
immediately without washing, then marked with [~4C]—conta1ning Ink, and
placed in a Kodak cassette with Kodak X—Omatic regular intensifying
screen, at —80°C overnight, but, not exceeding 16 h. The areas on the
chromatogram containing adducted nucleotides, as determined by the
autoradiography, were carefully cut out and assayed for [32P] content by
Cerenkov counting. Dilutions of 4 ul of the postlabeled samples were
also spotted on a separate PEI—cellulose plate (10 x 20 cm) and
developed to the top with 0.35 14 LIC1 buffer. The resolution pattern
generated, as determined by autoradiography, resulted in the separation
of excess [32P]—labeled p4iosphate away from the nucleotides.
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The spots containing radiolabeled nucleotides did not migrate from the
origin and were cut off separately and counted with a scintillation
counter to determine the amount of radioactivity present. The count
rates determined for all the samples were then used in determining the
total nucleotide labeling for each sample, which was then used in
computing relative adduct labeling.
Quantitative Estimation of DNA Adduct Levels
Relative adduct labeling (RAL) was estimated as described by Gupta
et al. (1982), using the formula;
CPM in Adducted Nucleotides
RAL~
CPM in Total Nomal Nucleotides
The count rate of normal and adducted nucleotides were used after
subtracting count rates In adjacent blank areas of the chromatogram.
7The RAL values were then multiplied by 1.0 x 10 and the computed value
represented the number of adducted nucleotides detected per total
nucleotides In sample tissue. The RAL (x 1O~) values were multiplied by
3 x 101 (i.e. the picomole of nucleotides derived from 1mg DNA, based on
the average molecular weight (309) of the four deoxyribonucleoside




preparation of Hepatic S9 Fractions for in vitro Mutagenesis AssaY
Hamster liver was carefully removed under sterile conditions,
rinsed thoroughly in sterile 20 m14 potassium phosphate buffer pH 7.4,
1.0 mM DTT, 1.0 mM EDTA and then homogenized in 20 mM potassium
phosphate buffer (4 volumes/g wet weight), supplemented with 0.15 M KC1,
1 mM EDTA and 1 mM Dir. The homogenate was centrifuged at 10,000 x g
for 20 mm, at 4°C. The supernatant fraction (S9) was isolated and
distributed in 3 — 4 ml portions, into sterile tubes and stored at —800C
until needed. A small portion of the S9 was used to estimate protein
content and NAT activity.
Preparation of S9 Mix
As described In Maron and Ames (1983), each ml of S9 mix prepared
was composed of 8 mM MgCl2, 33 mM KC1, 5 mt4 glucose—6—phosphate, 4 mM
NADP, 10 mM sodium phosphate buffer pH 7.4, and S9 preparation adjusted
to a final protein concentration of 1 mg/mi or a concentration range of
0.2 mg/mi to 2.0 mg/mi In dose—response assays. All reagents were
prepared fresh, sterile and constantly kept cold on ice for each assay.
UhlLU,~ II
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PreDaration of Vogel—Bonner E Salts
The stock salt solution was prepared by placing 670 ml warm water
in a beaker with magnetic stirrer, then 10 g of magnesium sulfate, 100 g
citric acid monohydrate, 500 g dibasic potassium phosphate and 175 g
sodium ammonium phosphate were added In the order listed. Each salt was
allowed to dissolve completely before adding the next. The volume was
adjusted to 1 liter and the solution was distributed into two 1 liter
glass bottles, autoclaved for 20 mi.n at 121°C, allowed to cool and then
stored refrigerated until needed.
PreDaratlon of Minimal Glucose A~ar Plates
Minimal glucose agar was prepared as described in Maron and Ames
(1983), by dissolving 15 g Bacto agar in 930 ml distilled water. The
mixture was autoclaved for 20 mm at 121°C. When the mixture had cooled
to about 60°C, 20 ml of the sterile Vogel—Bonner salt solution and 50 ml
of a sterile 40% glucose solution were added and thoroughly stirred.
About 30 ml of the mixture were poured into 15 x 100 mm plastic Petri
dishes. These plates were stored cool under sterile conditions, but
allowed to warm up to room temperature before being used in mutagenesis.
assays, where they were overlayed with reaction mixture.
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Preparation of Nutrient Agar Broth
Nutrient agar broth for growing Salmonella typhimurium strain TA98
was prepared as previously described by Maron and Ames (1983). This was
achieved by dissolving 8 g Bacto nutrient broth and 5 g NaC1 in 1 liter
distilled water. The mixture was. autoclaved at 121°C for 20 mm,
allowed to cool and stored refrigerated in a sterile bottle until
needed.
Preparation of T0D Agar.
This was prepared. as described by Maron and Ames (1983), by
dissolving 6 g Bacto agar and 5 g NaCl in 1 liter of distilled water.
The mixture was .autoclaved at 121°C for .20 mm. The agar was stored
refrigerated In a glass bottle and when needed, it was heated to melt.
Each 100 ml of melted top agar was then supplemented with 10 ml of a
sterile histidine/biotin (125 uM each) mixture , before being used for
mutagenesis assay.
Plate Incorporation Method of Salmonella TA98 Muta~enesis AssaY
The procedure developed by Ames at al. (1975) was used in this
study, with slight modifications. This involved adding a 20 ul volume
of top agar In a sterile 13 x 100 mm capped culture tube and placing the
tube in a dry bath at 45°C. The assay was started by adding to the
~il lL~~ I
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top agar, in sequence, 100 ul of a 16 h nutrient broth culture of
Salmonella tvohimurium strain TA98, 500 ul of 89 mix, 50 ul of
appropriate concentration of AF dissolved in DMSO, and 50 ul of an
appropriate concentration of AcCoA dissolved In distilled water or 50 Ui
of distilled water in assays where AcC0A was not used. Negative control
tubes contained bacteria, S9 mix , DMSO and water, and these were used
to establish the number of spontaneous revertants. Each assay condition
was run in duplicate or triplicate and the number of revertants in all
the plates were averaged as estimates of revertants per plate. The
assay tube was gently vortexed and poured Into the minimal glucose agar
plate. The plate was gently rotated and placed on a level surface until
the top agar hardened. The plate was capped and covered with opaque
material to avoid prolonged exposure to light before being incubated
0
inverted in the dark in a 37 C incubator. After 48 h incubation,
revertant colonies on test plates were counted with a semi—automatic
bacteria colony counter.
Pre—Incubation Method Salmonella TA98 Mutagenes.is Assay
The pre—incubation assay method used was a modification of the
plate incorporation method, that was first described by Yahagi et al.
(1975). This method enhances the detection of the mutagenicity of
chemicals that are poorly detectable in the plate Incorporation method.
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It also allows for smaller volumes, so that less AcCoA is needed in the
assay, and as well, the assay can be carried out at 370C which is more
natural for the activities of enzymes in the 89. The procedure involved
placing in a 13 x 100 mm sterile capped culture tube, 100 ul of a 16 h
nutrient broth culture of Salmonella TA98, 500 Ui S9 mix, 50 microliters
of an appropriate concentration of AF dissolved in DM80 and 50 ul of an
appropriate concentration of AcC0A dissolved in distilled water or 50 ul
of distilled water in assays where AcC0A was not used. Negative control
tubes contained TA98, S9 mix, DM80 and water, and these were used to
establish the number of spontaneous revertants. The assay components
were added in the sequence listed, so as to avoid placing bacteria In
direct contact with undiluted AF solution. Each assay condition was run
in duplicate or triplicate and the average of number of revertants in
all the plates was used as estimate of revertants per plate. The tube
was gently vortexed after adding all the components, then incubated for
30 mm with gentle shaking in a covered water bath at 37°C. At the end
of the incubation period, the assay mixture was transferred unto minimal
glucose agar plate with gentle rotation to allow for an even spread of
the top agar mix. The top agar mix was allowed to solidify in the dark
at room temperature, the plate was then Incubated inverted in the dark
In a 37°C Incubator. Plates were scored similarly to the plate
incorporation method at the end of a 48 h incubation period.
~~Ikhl~ h
.61
Estimation of Acetylator Genotvpe—DeDefldeflt Modulation of
AF Mutagenicity
The formula used for estimating the index of modulation of
mutagenicity was;
~t Rev in absence of AcC0A — # Rev in presence of .AcCoA
1—[ ]
# Rev in the absence of AcC0A
In this formula, “II Rev” represents the average number of TA98
Salmonella revertants counted per plate. The result of this formula,
when multiplied by 100, gives an estimate of the differential modulation
of the mutagenic activation of AF by hepatic S9 preparations derived
from slow and rapid acetylator hamsters. It defines a 100% reversIon of
the TA98 Salmonella strain when the activation system is not
supplemented with AcC0A, the required cofactor for N—acetyltransferase
to be operative. This data analysis was applied only to assays




NAT ActivitY in Bladder Eøithelial and Non—Epithelial Tissues
The epthellal layer of the blader lumen of rapid and slow
acetylator hamsters was carefully separated from the non—epithelial
layer and cytosolic preparations from each tissue were assayed for AcCoA—
dependent arylamine NAT activity. The level of PABA or AF NAT activity
was similar in both tissues, however, the NAT enzyme activity in tissue
preparations from rapid acetylator hamsters was significantly (p<O.05)
higher than in slow acetyator hamsters (Table 1). The expression of
equivalent levels of arylamine NAT activity in bladder epithelial and
non—epithelial tissues, coupled with the acetylator genotype—dependent
expression of this activity, provided a valid basis for the use of
cytosol derived from whole bladder in subsequent NAT activity
experiments.
Acetvlator Genotvoe—Depenaent Expression of Bladder
NAT Activity
AcCoA—dependent NAT activity in bladder cytosol preparations from
homozygous rapid acetylator (Blo. 87.20), slow acetylator
(Bio. 82.73/H), and their heterozygous Fl proqeny (Bio 87.20 x 82.73/H),
62
Table 1. AcCoA—Dependent Arylamine NAT Activity in Epithelial
and Non—Epithelial Hamster Bladder Tissue Cytosols
Hamster Acetylator NAT Activity (nmol/min/m~)
description genotype EDithelial Non—Epithelial
PABA AF PABA AF
Bio. 87.20 RR 17.2 + 50a 148b 184 ± 1.54
Bio. 82.73/H rr 0.59 ± O.22~ 0032b 0.12k ± 0 018C 0.086
~PABA NAT data values represent Mean ± SEt4 for duplicate
determinations in pooled bladder tissues from six individual male
AF NAT data values are single determinations in pooled bladder
tissues.
C
PABA and AF NAT activity in slow (rr) acetylator was




expressed a gene dose—response relationship for PABA, PAS and AF NAT
activity (Table 2). NAT activity in homozygous rapid and slow
acetylator hamster bladder cytosol differed about 150—fold for PABA,
75—fold for PAS and 5—fold for AF. In another comparison of bladder NAT
activity between homozygous rapid (MHA/SsLak), homozygous slow
(Blo. 82.73/H) and the heterozygous (MHA/SsLak x Blo 82.73/H) acetylator
hamsters, a gene dose—response relationship was expressed towards PABA
(Fig. 1), PAS (Fig. 2) and the carcinogenic arylamines AF (Fig. 3), ABP
(Fig. 4), as well as BNA (Fig. 5). Bladder cytosol PABA and AF NAT
activity in the homozygous rapid acetylator MHA/SsLak and Bio. 87.20
were similar (Tables 2 and 3). The Fl progenies Bio. 87.20 x 82.73/H
(Table 2) and MHA/SsLak x Bio. 82.73/H (Table 4) expressed a unimodal
distribution of arylamine NAT activity Intermediate between the
homozygous rapid and slow acetylator parental strains. These acetylator
genotype—dependent capacities for arylamine NAT activity in hamster
bladder cytosol are similar to the observations made in a detailed study
of inheritance pattern of hamster bladder NAT activity, reported by Hem
et al. (1987b) and are concordant with acetylator genotype—dependent
expression of hamster hepatic cytosol NAT activity (Hem at al., 1985;
Trinidad et al., 1989).
~JII~~
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Table 2. Acetylator Genotype—Dependent Expression of Arylamine
NAT Activity in Hamster Bladder Cytosol.
Hamster Acetylator N NAT Activity (nmol/min/mg)
strain qenotyoe PABA PAS AF
Blo.87.20 RR 4 10.6 ± 1.1 4.96 ± 1.11 4.0 ± 0.25
Fl Rr 6 4.20 ± 0.40 1.82 ± 0.13 3.04 ± 0.30
Bio. 82.73/H rr 8 0.069 ± 0.014 0.068 ± 0.016 0.94 ± 0.13
aTable values represent Mean ± SEM of arylamine NAT activity in
bun1dl~~idUal hamster bladder cytosol preparations.
PABA NAT activity differed significantly (P<0.000l) between
acetylator genotypes.
PAS and AF NAT activities differed significantly (P<0.005)
between acetylator genotypes.
Acetylator genotype is represented by homozygous rapid (RR)
homozygous slow and heterozygous Fl progeny (Rr) acetylators.
The number of hamsters from which bladders were pooled is
represented by N.
Fig. 1. Acetylator Genotype—dependent Expression of PABA NAT
Activity in Bladder Cytosol. RR represents homozygous
rapid acetylator, rr represents homozygous slow acetylator
hamster and Rr represents heterozygous Fl progeny. Data
values represent Mean ± SEM bladder cytosol NAT activity
(nmol/min/mg). Asterisks indicate that Mean PABA NAt
activities differed significantly (p<O.05) with respect to



























Fig. 2. Acetylator Genotype—Dependent Expression of PAS NAT
Activity in Hamster Bladder Cytosol. RR represents
homozygous rapid acetylator, rr represents homozygous slow
acetylator hamster and Rr represents heterozygous Fl
progeny. Data values represent Mean ± SEN bladder cytosol
NAT activity (•nmol/min 1mg). AsterIsks indicate that Mean
PAS NAT activities differed significantly (p<O.05) with





























Fig. 3. Acetylator Genotype—Dependent Expression of AF NAT
Activity in Hamster Bladder Cytosol. RR represents
homozygous rapid acetylator, rr represents homozygous
slow acetylator hamster and Rr represent heterozygous Fl
progeny~ Data values represent Mean ± SEN bladder cytosol
NAT activity (nmol/min/mg). Asterisks indicate that Mean
AF NAT activities differed significantly (p<O.05) with


































































































Fig. 4. Acetylator Genotype—Dependent Expression of ABP NAT
Activity in Hamster Bladder Cytosol. RR represents
homozygous rapid acetylator, rr represents homozygous slow
acetylator hamster and Rr represents heterozygous F)
progeny. Data values represent Mean ± SEM bladder cytosol
NAT activity (nmol/mln/mg). Asterisks indicate that mean
AF NAT activities differed significantly (p<O.05) with























Fig. 5. Acetylator Genotype—Dependent Expression of BNA NAT
Activity in Hamster Bladder Cytosol. RR represents
homozygous rapid acetylator, rr represents homozygous slow
acetylator hamster and Rr represents heterozygous Fl
progeny. Data values represent Mean ± SEM bladder cytosol
NAT activity (nmol/mln/mg). Asterisks indicate that Mean
BNA NAT activities differed significantly (p<O.05) with






















Table 3. Bladder Cytosolic NAT Apparent Maximum Catalytic Velocities
in Homozygous Rapid and Slow Acetylator Inbred Hamsters.
Animal Source Acetylator Apparent Vmax.
genotype (nmol/min/mg)
PABA NAT AR NAT
MHA/SsLak RR 9.65 ± 046a 6.20 ± 076b
Bio. 82.73/H rr 0.69 ± 010a 1.09 ± 037b
aPABA NAT activity was determined in the presence of 2.22 mM AcC0A,
and data value represents Mean ± SEM. The difference between RR
(MHA/SsLak) and rr (Blo. 82.73/H) acetylator genotypes (14—fold)
highly significant (P<0.01).
AF NAT activity was detemined in the presence of 2.0 mM AcC0A.
The difference between homozygous rapid and homozygous slow
acetylator hamster genotypes (6—fold) is highly significant
(P<0.05)
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Table 4. Anion—exchange FPLC of Arylamine NAT Activity in Bladder
Cytosol of Homozygous Rapid (RR) Heterozygous Fl Progeny
(Rr) and Homozygous Slow (rr) Acetylator Hamsters.
Acetylator NAT Actlvity(nmol acetylated/min)
EnzYme Source Genotvøe PABA PAS AF ABP BNA
Cytosol RR 560 390 84 58 68
Rr 82 40 33 25 21
rr 0.4 3 8 7 10
Polymorphic NATa RR 100 74 34 24 24
Rr 46 38 23 23 19
rr 0.3 2 3 4 7
Monomorphic NATb RR 1.4 1.3 5 6 7
Rr N.D. 0.6 2 2 2
rr ND. 2 2 3 3
Total Percent Recovery RR 18 19 46 52 56
Rr 56 97 76 100 100
rr 75 133 63 100 100
activity eluting in three fractions (3m1) at 120 mM KC1.
N.D. (none detected) represents non detectablable NAT activity
aData values for polymorphic fractions represent
bacti~hitY eluting in three fractions (3m1) at 60





Partial Purification of Bladder Cvtosollc NAT Activity
Bladder cytosol preparations derived from homozygous rapid
(MHA/SsLak) and slow (Blo. 82.73/H) acetylator hamsters were subjected
to anion—exchange FPLC. Two peaks of AcCoA—dependent AF (FIg. 6), ABP
(Fig. 7) and BNA (FIg. 8) NAT activities were separated. The first peak
activity eluted at 60 mM KC1, while the second peak eluted at 120 mM
KC1. Only one peak of AcCoA—dependent PABA (Fig. 9) and PAS (FIg. 10)
NAT activity eluting at 60 mM KC1 was detectable with the assay
procedure used. This single peak was distinctly expressed with
cytosolic preparations from homozygous rapid (RR) and heterozygous Fl
progeny (Rr) acetylator hamsters. The total percent of arylamine NAT
activity recovered In the monomorphic and polymorphic enzyme fractions
following partial purification of crude cytosol, varied between the
hamster acetylator genotypes. About 18 to 56 percent total recoveries
were observed for PABA, PAS, AF, ABP and BNA NAT activity in the
partially purified isozymes derived from rapid acetylator hamsters. In
the heterozygous Fl progeny the total percent recovery ranged from 56 to
100 percent, while in the homozygous slow acetylatar, percent total
recovery of arylamine NAT activity ranged from 63 to 100 percent for all
the substrates tested. The total bladder NAT activity, for arylamines,
detected In cytosolic preparations and the partially purified isozymes
Fig. 6. Anion—Exchange FPLC of AF NAT Activity in Bladder Cytosol
of Homozygous Rapid Acetylator (RR), Heterozygous
acetylator (Rr) and Homozygous Slow Acetylator (rr)
Hamsters. AF NAT activities In nmol/mln/ml are plotted on
the ordinate versus fraction number on the abscissa. The
cytosolic protein applied to the column was between
10 — 20 mg for each genotype. The KC1 gradient (in H x 10)
applied is shown as dashed line in the upper panel.
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Fig. 7. AnIon—Exchange FPLC of ABP NAT Activity in Bladder Cytosol
of Homozygous Rapid Acetylator(RR), Heterozygous Acetylator
(Rr) and Homozygous Slow Acetylator (rr) Hamsters. ABP NAT
activities in nmol/min/ml are plotted on the ordinate
versus fraction number on the abscissa. The cytosolic
protein applied to the column was between 10 — 20 mg for
each genotype. The profile of the KC1 gradient applied Is
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Fig. 8. Anion—Exchange FPLC of BNA NAT Activity In Bladder Cytosol
of Homozygous Rapid Acetylator (RR), Heterozygous
Acetylator (Rr) and Homozygous Slow acetylator (rr)
Hamsters. BNA NAT activities in nmol/min/ml are plotted on
the ordinate versus fraction number on the abscissa. The
cytosolic protein applied to the column was between
10 — 20 mg for each genotype. The profile of the KCl


























Fig.. 9.. Anion—Exchange FPLC of PABA NAT Activity in Bladder Cytosol
of Homozygous Rapid Acetylator (RR), Heterozygous
Acetylator (Rr) and Homozygous Slow Acetylator (rr)
Hamsters. PABA NAT activities in nmol/min/ml are plotted
on the ordinate versus fraction number on the abscissa.
The cytosolic protein applied to the column was between
10 — 20 mg for each genotype. The profile of the KC1































0 8 16 24 32
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Fig. 10. AnIon—Exchange FPLC of PAS NAT Activity In Bladder Cytosol
of Homozygous Rapid Acetylator (RR), Heterozygous
Acetylator (Rr) and Homozygous Slow Acetylator (rr)
H~unst.ers. PAS NAT activities in nmol/mln/ml are plotted
on the ordinate versus fraction number on the abscissa.
The cytosolic protein applied to the column was between
10 — 20 mg for each genotype. The profile of the KC1
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are outlined in Table 4. The table shows acetylator genotype—dependent
expression of arylamine NAT activity in cytosolic preparations as well
as in the first eluting partially purified NAT isozyme. Thus, for each
substrate tested, the cytosol and the first eluting isozyme expressed
highest levels of bladder arylamine NAT activity with the homozygous
rapid acetylators, an intermediate level in the heterozygous Fl
progenies, and very low or non—detectable levels in the homozygous slow
acetylators (Table 4). In contrast, arylamine NAT activity in the
second e1uting peak was less than that of the first peak and it
exhibited acetylator genotype—independent arylamine NAT activity. The
first peak is therefore referred to as the polymorphic NAT isozyme,
while the second peak is referred to as the monomorphic NAT isozyme.
Michaelis—Menten Kinetic Constants of PABA NAT Activity in
Hamster Bladder Cytosol
PABA NAT activity was determined with various concentrations of
PABA, using crude bladder cytosols derived from homozygous rapid and
slow acetylator hamsters (FIg. 11 and Fig. 12). MIchael is—Menten
kinetic Constants were derived from Eadie-Hofstee plots (Table 5).
Bladder cytosolic preparations of rapid acetylator hamsters had apparent
PABA NAT Vmax values (9.65 ± 0.46 nmol/min/mg) greater than in slow
acetylators (0.69 ± 0.10 nmol/min/mg), while the apparent PABA Km value
Fig. 11. AcCoA—Dependent PABA NAT Activity in Homozygous Rapid (RR)
Acetylator Hamster Bladder Cytosol in the Presence of
Various PABA Concentrations. NAT activity In nmol/min/mg
is plotted on the ordinate versus micromolar PABA
concentration on the abscissa. Data points represent














Fig. 12. AcCoA—Dependent PABA NAT Activity In Homozygous Slow (rr)
Acetylator Hamster Bladder Cytosol in the Presence of
Various PABA Concentrations. NAT activity In nmol/min/mg
is plotted on the ordinate versus micromolar PABA
concentration on the abscissa. Data points represent
duplicate determinations in pooled bladder cytosol.
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Table 5. Michaelis—Mefltefl Kinetic Constants of Rapid (RR) and
Slow (rr) Acetylator Hamster Bladder PABA NAT Activity
Acetylator Genotype PABA Apparent Vmax PABA Apparent Km
(nmol/min/mg) (UN)
RR 9.65 ± 046a 131 ± 12b
rr 0.69 ± 010a 426 ± 117
GTable values represent Mean ± SEN PABA NAT activity in pooled
bladder cytosol Ic preparations. Michael Is—Nenten kinetic constants
were derived from data subjected to Eadie—Hofstee analysis. NAT
activity was determined in the presence of 2.22 mM AcC0A and PABA
concentration ranged from 50 to 500 uM with the rapid
acetylator cytosol and 150 to 1000 UN with the slow
acetylator cytosol. For homozygous rapid acetylator cytosol, the
correlation coefficient for linear regression of the Eadle—Hofstee
analysis was 0.992, while that of the slow acetylator was 0.901.
83
(131 ± 12 uM) was less than that computed for the slow acetylator (426 ±
117 uM) (Table 5).
Michaelis—Menten Kinetic Constants of AcCoA for PABA NAT Activitv~
in Hamster Bladder Cytosol
ACCoA Is a required cofactor for NAT activity to be expressed. To
determine the effect of this cofactor on cytosolic arylamine NAT
activity in vitro, PABA NAT activity in crude bladder cytosol, derived
from homozygous rapid and slow acetylator hamsters, was determined in
the presence of various AcC0A concentrations (Fig. 13 and Fig. 14).
Michaelis—Menten kinetic constants were derived from Eadie—Hofstee plots
of PABA NAT activity in the presence of 0.22 mM PABA and AcC0A
concentrations ranging from 100 to 2250 uM. Under this assay condition,
the AcC0A apparent Vmax with homozygous rapid acetylator bladder cytosol
was 243 ± 2.7 nmol/min/mg, about 47—fold greater than in the homozygous
slow acetylator (0.52 ± 0.01 nmol/min/mg) (Table 6). The apparent NAT Km
for AcC0A under the same conditions was 2.66 ~ 0.37 mM in homozygous
rapid acetylator hamster bladder cytosol and 026 ± 0.1 mM in the slow
acetylator bladder cytosol (Table 6).
Fig. 13. AcCoA—Dependent PABA NAT Activity In Homozygous Rapid (RR)
Acetylator Hamster Bladder Cytosol In the Presence of
Various AcCoA Concentrations. NAT activity expressed in
nmol/min/mg Is plotted on the ordinate versus micromolar
AcC0A concentration on the abscissa. Data points
represent duplicate determinations in pooled bladder











Fig. 14. AcCoA—Dependent PABA NAT Activity in Homozygous slow (rr)
Acetylator Hamster Bladder Cytosol in the Presence of
Various AcC0A Concentrations. Dependence of NAT Activity
in Homozygous Slow Acetylator (rr) Bladder Cytosol on
AcC0A concentration. NAT activity in nmol/min/mg is
plotted on the ordinate versus micromolar AcC0A
concentration on the abscissa. Data points represent
duplicate determinations in pooled bladder cytosol, In the
presence of 0.22 mM PABA.
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Table 6. Michaelis—Menten Kinetic Constants of AcC0A•
for PABA NAT Activity in Hamster Bladder Cytosol
Acetylator Genotype PABA Apparent Vmax AcCoA Apparent Km
(nmol/min/mg) (ut4)
RR 24.3 ± 27a 2.66 ± 037~
rr 0.52 ± 0.01 0.26 ± 0.01
PABA NAT activity was determined in the presence of 0.22 mM PABA.
Table values represent Mean ± SEM of PABA NAT activity in pooled
bladder cytosolic preparations derived from homozygous rapid (RR)
and homozygous slow (rr) acetylator hamsters, in the presence of
AcC0A concentrations ranging from 100 to 2250 uM
Michaelis—Menten kinetic constants were derived from data
subjected to Eadie—Hofstee analysis. For homozygous rapid
acetylator cytosol the correlation coefficient for linear
of the Eadie—Hofstee analysis was 0.972.
For homozygous slow acetylator cytosol, the correlation
coefficient for linear regression of the Eadie—Hofstee analysis
was 0.997.
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Michaelis—Menten Kinetic Constants of AF NAT Activity In
Bladder Cvtosol. FPLC—Derived Polymorphic and Monomorphic
NAT Isozvme Fractions
NAT activities were determined in crude bladder cytosol, and In
anion—exchange FPLC—derived polymorphic and monomorphic NAT isozymes,
using various concentrations of AF (Figs. 15 — 18). Mlchaelis—Menten
kinetic constants were derived from Eadie—Hofstee plots. The apparent
Vmax of AF NAT activity in the homozygous rapid acetylator bladder
cytosol (6.2 ± 0.76 nmol/mln/mg) was about 6—fold greater than in the
slow acetylator cytosol (1.09 ± 0.37 nmol/mln/mg) (Table 7). The
apparent Vmax for AF NAT activity was higher in the polymorphic isozyme
than in the cytosol and, similar to the pattern with cytosols, the rapid
acetylator polymophic isozyme had an apparent Vmax AF NAT activity
(92.4 ~ 9.3 nmol/min/mg) about 50—fold greater than that of the slow
acotylator (1.99 ± 1.19 nmol/min/mg) (Table 7). In contrast, the
apparent Vmax of AF NAT activity with the monomorphic isozyme did not
differ significantly (p>0.05) between the two acetylator genotypes
(Table 7).
The apparent NAT Km for AF in the presence of 2.0 mM AcCoA was
consistently higher in the homozygous rapid acetylator enzyme
preparations (cytosol, polymorphic and monomorphic isozyme) than in
their homozygous slow acetylator equivalents (Table 7).
Fig. 15. AcCoA—Dependent AF NAT Activity in Partially Purified
Polymorphic NAT Isozyme Derived From Homozygous Rapid
Acetylator (RR) Hamster Bladder Cytosol in the Presence of
Various AF Concentrations. AF NAT activity (nmol/min/mg)
is plotted on the ordinate versus AF concentration
(micromolar) on the abscissa. Each data point represents
an average of four determinations in the preserce of
2.22 mM ACC0A. The inset figure represents Eadie—Hofstee
transformations of the data. The ordinate data are






































Fig. 16. AcCoA—Dependent AF NAT Activity in Partially Purified
Monomorphic NAT Isozyme Derived From Homozygous Rapid
Acetylator (RR) Hamster Bladder Cytosol in the Presence of
Various AF Concentrations. AF NAT activity (nmol/min/mg)
Is plotted on the ordinate versus AF concentration
(micromolar) on the abscissa. Each data point represents
an average of four determinations in the presence of
2.22 mM AcCoA. The inset figure represents Eadle—Hofstee
transformations of the data. The ordinate and abscissa
data are represented as multiples of 10~.

Fig. 17 AcCoA—Dependent AF NAT Activity in Partially Purified
Polymorphic NAT Isozyme Derived From Homozygous Slow (rr)
Acetylator Hamster Bladder Cytosol in the Presence of
Various AF Concentrations. AF NAT activity (nmol/min/mg)
Is plotted on the ordinate versus AF concentrations
(micromolar) on the abscissa. Each data point represents
an average of six determinations in the presence of
222 mM AcC0A. The inset figure represents Eadie-+lofstee
transformations of the data. The ordinate data are
represented as multiples of 101 and those of the abscissa
as multiples of 101. The abscissa data of the inset
figure are represented as multiples of i02.























Fig. 18. AcCoA—Dependent AF NAT Activity in Partialily Purified
Monomorphic NAT Isozyme Derived From Homozygous Slow
Acetylator (rr) Hamster Bladder Cytosol In the Presence of
Various AF Concentrations. AF NAT activity (nmol/min/mg)
is plotted on the ordinate versus AF concentration
(micromolar) on the abscissa. Each data point represents
an average of four determinations in the presence of
2.22 mM AcC0A. The inset figure represents Eadie—Hofstee
transformations of the data. The abscissa data are
represented as multiples of 101, while for the inset
figure they are represented as multiples of 101.
T6
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Table 7. Michaelis—Mentefl Kinetic Constants of Hamster Bladder
AF NAT Activity.
Enzyme Acetylator N Apparent Vmax apparent Km
source ~enotvoe (nmol/min/m~) (uM)
Cytosol RR 5 6.20 ± 0.76 109 ± 30.00
Cytosol rr 4 1.09 ± 0.37* 17.2 ± 16.10
Polymorphic NAT RR 4 92.4 ± 9.30 168 ± 83.00
Polymorphic NAT rr 6 1.99 ± 1.19* 8.71 ± 6.63
Monomorphic NAT RR 4 21.2 ± 12.00 6.32 ± 2.17
Monomorphic NAT rr 4 5.72 ± 4.12* 0.68 ± 0.21
Table values represent Mean ± SEM of AF NAT activity in pooled
bladder cytosolic fractions and partially purified FPLC isozyme
fractions. Asterisks indicate homozygous rapid acetylator (RR)
cytosolic or polymorphic NAT apparent Km and Vmax significantly
(p<O.005) higher than homozygous slow acetylator (rr) NAT
equivalent following Neuman—Keuls multiple range analysis. No other
differences were significant (P>0.05) following this analysis..
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Analysis of EnzymatlcallY Synthesized [32PIATP bY
PEI—CelluloSe Thin Layer Chromatography
Two autoradiograms of thin layer chromatograms of 0.2 ul (about
250 uCi) aliquots of the [32P]ATP reaction mixture showed large spots of
radioactivity which migrated a few centimeters away from the origin
after resolving the chromatogram in 1.2 N L1C1 (Fig. 19). The
chromatography procedure was used to determine if the radiolabeled
reaction mixture was contaminated with excess [32P]phosphate which would
have migrated a few centimeters above the [32P]ATP spot. The absence of
contaminating radioactivity in the reaction mixture suggested that the
reaction mixture was suitable for the subsequent [3~P] phosphorylation
of nucleotides In the DNA digest that were assayed for adducts. An
allquot (3 ul) of the [32P]ATP reaction mixture was also used in
estimating the activity Cud/mi) of the radiolabeled ATP. The activity
of preparations in this study were usually about 150 to 250 uCi/mi. The
volume of the reaction mixture was then adjusted to deliver 250 uCi per
1.1 ml of labeling mixture containing DNA hydrolysates.
Fig. 19. Autoradiograms of One—Dimensional Chromatography of
Enzymatically Synthesized [32P)ATP. A 0.5 ul aliquot of
the [32P]ATP reaction mixture was spotted at the bottom
of a 5 x 10 cm PEI— cellulose plate and chromatographed
In 1.5 M Lid. This autoradiogram was obtained after a
5 mm exposure of the plate. Arrows indicate the origin
where the reaction mixture was spotted (origin) and the






P~—Cellulose Thin Layer Chrornatpgraohic Analysis of
[ P1—labeled Hamster Tissue DNA Digests
An autoradiogram of DNA digests following initial spotting on PEI—
cellulose plate is shown In Fig. 20. Careful and consistent spotting of
post—labeled digests on pre—marked spots on the plate prevents extensive
diffusion of nucleotides away from the origin before development with
resolving buffer. This also allows for better resolution of adducts.
One—dimensional chromatography in 0.8 N sodium phosphate buffer
pH 6.8, separated the four nucleotide species (cytosine, adenine,
thymine and guanosine) in DNA digests and excess [32P]—labeled
phosphate into distinct spots (Figs. 21 and 22). The presence of
adequately labeled nucleotides and the absence of contaminating spots at
the origin or any other part of the plate Indicated that the DNA samples
analyzed had been digested to completion. In addition, it showed that
there was no preferential labeling of one of the nucleotide species
present In the DNA hydrolysate with the labeling conditions used.
One dimensional chromatography in 0.35 N LiCl separated excess
[32P]—labeled phosphates (P1), in DNA digests, away from the total
[32P]—labeled nucleotides (Fig. 23). The radioactivity present in
nucleotide spots from the LiCi treated plates was determined by Cerenkov
counting and used in computing total nucleotide labeling.
Fig. 20.. Autoradiogram of PEI—cellulose Plate after spotting
32[ P]—postlabeled DNA Digest Samples at Pre—marked Points




Fig. 21. Autoradlogram of One—Dimensional Chromatography of [32P]—
Postlabeled DNA Digests Derived From Livers of Untreated
(lane II), AF Treated Hamsters (lanes III to VI), and a
Standard DNA—AF Adduct (lane I). Development was in 0.8 t4
sodium phosphate buffer, pH 6.8. The Pi spots are excess
32[ P3-labeled phosphates, while C, A, T and G represent
[32P]—labeled cytosine, adenine, thymine and guanine,
respectively.
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Fig. 23. Autoradiogram of One—Dimensional Chromatography of [32P]—
Postlabeled DNA Digests derived From Hamster Liver DNA
(lanes II to VIII) and a Standard DNA—AF Adduct Sample
(lane I). Development was in 0.35 M Lid. The top spots
32
(P1) represent excess [ P]—labeled phosphates, while the
32
bottom spots (nucleotides) are total ( P]—labeled
nucleotides present in DNA digests.
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P~—Cellulose Thin Layer Chromatographic AnalYsis of
[ P1—Labeled Arvlamine—DNA Adducts In Hamster Liver and Bladder
After the final chromatography (04), the PEI—cellulose plate was
washed by rinsing in distilled water, air—dried and then subjected to
autoradiography. The areas containing arylamine—DNA adduct, as
determined by corresponding standard adduct spot, were assayed by
Cerenkov counting. Only the DNA—AF adduct was detectable in hepatic DNA
digests of hamsters 3 h following AF treatment (Fig. 24). Nucleotides
adducted with AAF which would have been resolved a few centimeters above
the DNA—AF adduct were not detected. The standard AF adducted DNA spot
is shown in the lane marked ‘S” (Fig. 24). Lanes I and II show DNA—AF
adducts from slow acetylator hamsters and lanes III and IV were from
rapid acetylators. Lane V was spotted with DNA digests from an
untreated hamster and It indicates the absence of any adducted
nucleotides.
PEI—cellulose chromatography of DNA digest derived from standard
ABP— (lane I), AAF— (lane II) and AF—adducted (lane III) DNA show the
relative distances these adducts migrated from the origin, with the
DNA—ABP adduct and DNA—AAF adduct migrating about the same distance,
while the DNA—AF adduct migrated a shorter distance from the origin
(Fig. 25). The DNA—ABP adduct level was estimated to be about
4.9 picomoles/mg DNA, that of the DNA—AAF adduct was about
Fig. 24. Autoradiogram of One—Dimensional Chromatography of’
Postlabeled DNA Digests Derived from Hamster Livers, 3 h
Following AF Treatment. Standard AF adducted DNA digest
was spotted in lane 5, lanes I and II are digests from
slow acetylator hamsters, lanes III and IV are digests
from rapid acetylator hamsters and lane V is a digest
from an untreated hamster. Arrow indicates region where
the DNA—AF adduct was localized. The chromatographic






Fig. 25. Autoradiogram of One—dimensional Chromatography of [32P3—
Postlabeled DNA Digests Derived from Hamster Livers, 18 h
Following Treatment . Standard ABP adducted DNA digest
was spotted in lane I, standard AAF adducted DNA digest
in lane II, standard AF adducted DNA digest in lane III,
AF treated slow acetylator hamster DNA digest in lanes
IV, V and VI, and AF treated rapid acetylator hamster DNA
digests in lanes VII and VIII. Chromatographic procedure
is described in “Materials and Methods” section. Arrows






























34.8 picomoles/mg DNA, while that of the DNA—AF adduct was about
1500 plcomoles/mg DNA, in this study. The DNA—AF adduct spots in lanes
IV, V and VI, were derived from hepatic DNA digests derived from slow
acetylator hamsters, and those in lanes VII and VIII were from rapid
acetylator hamsters, 18 h following AF treatment (Fig. 25).
Tissues from ABP treated hamsters were also analyzed for adduct
levels (Fig. 26). DNA digests from standard ABP adducted DNA was
spotted in the lanes marked I, lane II was spotted with DNA digests
derived from the bladder of an untreated slow hamster. Lanes III and IV
are hepatic DNA digests from slow acetylator hamsters, and lanes V and
VI are hepatic DNA digests from rapid acetylator hamsters. Lanes VII
and VIII were spotted with DNA digest derived from bladders of slow and
rapid acetylator hamsters respectively.
Fig~. 26. Autoradiogram of One—Dimensional Chromatography of [32P]—
Postlabeled DNA Digests Derived from Hamster Livers and
Bladders, 18 h Following ABP Treatment. Standard ABP
adducted digest is spotted In lane I, untreated rapid
acetylator hamster bladder DNA digest in lane II, ABP
treated slow acetylator hamster liver DNA digests in
lanes III and IV, ABP treated rapid acetylator hamster
liver DNA digests in lanes V and VI, ABP treated slow
acetylator hamster bladder DNA digests in lane VII, ABP
treated rapid acetylator hamster bladder DNA digests in
lane VIII. Chromatographic procedure is described in























Estimation of Levels of N—(deoxvauanosin—8—Y1)—AF or —ABP Adducts
formed in Hepatic and Bladder Tissues of Raoid and Slow Acetylator
Hamsters Administered (i.o.) 60 mg/kg AF or ABP
Arylamine carcinogens can be metabolized in vitro or iii vivo to
electrophiles which bind to DNA to form adducts. The covalent
interaction of arylamine carcinogens with DNA Is considered an essential
step in the initiation of carcinogenesis in target tissues. The
N—(deoxyguanosin--8—yl)—arYlamifle adduct species has been identified as
the predominant and a persistent adduct formed during arylamine—induced
genotoxicity.
In a comparative study of the effect of acetylator—genotype on DNA
arylamine—induced genotoxicity, adduct levels were measured in rapid and
slow acetylator hamster liver and bladder following treatment with
arylamine. The levels of DNA—AF adduct detected in the liver of rapid
and slow acetylator hamsters did not differ significantly (p>0.1), 3 h
following treatment (Figs. 27 and 29 and Table 8). In contrast to the
3 h adduct level, at 18 h after treatment, hepatic ONA—AF adduct levels
in slow acetylator hamsters (24.8 ± 5.5 picomoles/mg DNA) were
significantly (p~0.001) higher than rapid acetylator (17.4 ± 2.2
picomoles/mg DNA) hamsters (Figs. 28 and 29 and Table 8).
Fig. 27. Levels of N—(deoxyguanosin—8—yl)—AF DNA Adduct Formed in
Livers of Hamsters 3 h after Treatment with 60 mg/kg AF.
Each bar represents Mean ± SD adducts (picomoles/mg DNA)
determined in duplicate [32P]—postlabellng chromatography
of DNA digests derived from a single hamster. Hamster
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Fig. 28. Levels of N—(deoxyguanosln—8—yl)-AF DNA Adduct Formed in
Livers of Hamsters 18 h after Treatment with 60 mg/kg
AF. Each bar represents Mean ± SD adduct (picomoles/mg
32DNA) determined in duplicate [ P]—postIabeling
chromatography of DNA digests derived from a single
hamster. Adduct -value for bar with asterisk was obtained
from one chromatogram. -Hamster acetylator genotype Is
























































Fig. 29. Time-Response Curve Showing N—(deoxyguanosln—8—yl)-AF DNA
Adduct Levels Determined in Livers of Hamsters, 3 h and
18 h Following Treatment with 60 mg/kg AF. The 3 h data
points represent Mean ± SEM of adduct (picomoles/mg DNA)
detected in duplicate [32P]—postlabellng chromatography
of DNA digests derived from three rapid (RR) and slow
(rr) acetylator hamsters. The 18 h data points were
obtained with DNA digests derived from seven hamsters
each of rapid or slow acetylator genotype. Closed
circles represent rapid acetylator and open triangle
represent slow acetylator.







































Table 8. N—(deoxyguanosin—8—Yl)—AF DNA Adduct Levels in Homozygous
Rapid (RR) and Slow (rr) Acetylator Hamsters Following a
Single Intraperitoneal Injection of 60 mg/kg AF
Tissue/ Treatment N N—(dGuo—8—yD—AF Significance
Acetylator (picomoles adduct/mg DNA) (RR vs rr)
aenotvDe
RR 3 14.4 ± 4.1
Liver 3 h N.S.
rr 3 10.7 ± 2.5
RR 7 17.4 ± 2.2
Liver 18 h p 0.001
rr 7 24.8 ± 5.5
RR 3 3.3±0.8
Bladder 18 h p 0.015
rr 3 6.9±1.3
D~a values represent Mean ± SD of.adduct determined in duplicate
t P]—postlabeling chromatography of DNA digests derived from
hamster liver and bladder tissues.
The number of hamsters used for each determination is indicated by
“N. Liver and bladder tissues were extracted from hamsters 3 h or
18 h following treatment with AF. Hamster acetylator genotype is
represented by rapid (RR) and slow (rr).
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The DNA—AF adduct level detected in hamster bladder tissues was lower
than in hepatic tissues, 18 h following treatment (Fig 30).
Furthermore, rapid acetylators (11.0 ± 2.8 picomoles/mg DNA) expressed
significantly (p 0.02) higher bladder DNA—AF adduct levels than slow
acetylators (6.9 ± 1.3 picomoles/mg DNA).
~_(deoxyguafloSifl_8_yl)_aCetYlamlfl0U0r~t~ adduct was also detected
In hamster liver tissues 18 h following treatment. This acetylated
adduct constituted only about 10% of the total adducts detected in liver
tissues. The level of the acetylated adduct did not differ between
rapid (1.9 ± 0.9 picomoles/mg DNA) or slow (1.1 ± 0.7 plcomoles/mg DNA)
acetylator hamsters, nor was there any consistency in the expression of
this adduct.
Hamster hepatic and bladder tissues were also examined following
ABP treatment. The levels of hepatic DNA—ABP adduct detected in slow
acetylator (9.7 ± 2.7 picomoles/mg DNA) were significantly (p<0.003)
higher than in rapid acetylator (4.3 ± 1.3 picomoles/mg DNA) hamsters,
18 h following treatment (Fig. 31 and Table 9). However, bladder
DNA—ABP adduct was expressed at significantly (p~0.001) higher levels in
rapid (4.3 ± 1.3 picomoles/mg DNA) than in slow (2.3 ± 0.7 picomoles/mg
DNA) acetylator hamsters (Fig. 32 and Table 9)
Fig. 30. Levels of N—(deoxyguanosln—8—Yl)—AF DNA Adduct Formed in
Bladders of Hamsters 18 h Following Treatment With
60 mg/kg AF. Each bar represents Mean ± SD adduct
32
(picomoles/mg DNA) determined in duplicate t P1—
postlabeling chromatography of DNA digests derived from a
single hamster bladder. Hamster acetylator genotype Is


































Fig 31. Levels of N—(deoxyguanosin—8—yl)—ABP DNA Adduct Formed in
Livers of Hamsters 18 h Following Treatment With 60 mg/kg
ABP. Each bar represents Mean ± SD adduct (picomoles/mg
DNA) determined in duplicate [32P]—post—labeling
chromatography of DNA digests from a single hamster.
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Fig 32.. Levels of N—(deoxyguanosin—8—y1)—ABP DNA Adduct Formed in
Bladder of Hamsters 18 h Following Treatment With 60 mg/kg
ABP. Each bar represents Mean ± SEM adduct (picomoles/mg
DNA) determined in duplicate [32P]—postlabeling
chromatography of DNA digests derived from a single hamster
bladder.. Adduct level for bar with asterisk was obtained
from one chromatogram. Hamster acetylator genotype is













































Table 9. N—(deoxyguanoslfl—8Y1)’ABP DNA Adduct Levels
Rapid and Slow Acetylator Hamsters Following
Intraperitoneal Injection of 60 mg/kg ABP
in HomozygOuS
a Single
Tissue! Treatment N N—(dGuo—8—yl)—ABP Significance
Acetylator (picomoles adduct/mg DNA)
genotvDe (rr versus RRI
RR 3 4.3±1.3
Liver 18 h p 0.003
rr 3 9.7±2.7
RR 1 2.0±0.1
Bladder 3 h N.S.
rr 1 1.2±0.1
RR 6 4.3±1.3
Bladder 18 h p 0.001
rr 6 2.3±0.7
D~a values represent Mean ± SD of adduct determined In duplicate
[ P3—post—labeling chromatography of DNA digests derived from
liver and bladder of homozygous rapid (RR) and homozygous slow (rr)
acetylator hamsters. The number of hamsters used for each
determination is indicated by “N’. Liver and bladder tissues were
extracted from hamsters 3 h or 18 h following ABP treatment.
~thU~L~ — -
115
DNA—ABP adduct levels in bladder tissues of hamsters were also
determined, 3 h following treatment, and the rapid acetylator had higher
adduct level compared to the slow acetylator hamster (Table 9). The
significance of the observed differences in DNA—ABP adduct levels in
bladder tissues at the 3 h time point could not be be determined in view
of the fact that only one hamster of each acetylator genotype was
examined.
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Comparisons of t4utagentc Activation of AF With HepatiC S9
preparations Derived From Rapid and Slow Acetvlator Hamsters
Hepatic 89 preparations derived from both rapid and slow acetylator
hamsters readily activated different concentrations of AF to mutagens in
Salmonella TA98 mutagenesis assays. The mutagenic activation of AF by
hamster hepatic 89 preparations exhibited typical saturation kinetics
and did not differ between acetylator genotypes (Figs. 33, 34 and 35).
When 77 uM AF was used in the mutagenesis assay mix, the capacity for
activation appeared.to peak with 89 preparations containing about 1
mg/ml protein (Fig. 35). Thus, in subsequent mutagenesis assays, the
protein concentration in S9 preparations was adjusted to 1 mg/ml in the
reaction mix.
Mutapenic Activation of AF with Hepatic 89 Preparations Derived
From Raøid and Slow Acetvlator Hamsters in the Presence of Ac~oA
Initial AF mutagenesis assays, using the pre—Incubation method,
indicated that the addition of AcCoA to hamster hepatic S9 preparations
resulted in a dose—dependent reduction in mutagenic activation compared
to the activity in the absence of AcC0A (Fig. 36). AcC0A is a required
cofactor for the expression of NAT activity during arylamine
N—acetylation. It is however conceivable that there is a critical
dilution of this cofactor in the preparative steps of hepatic S9
Fig. 33. Mutagenic Activation of AF with Hamster
Hepatic S9 Preparations. Mutagenicity of AF was assayed
with Salmonella tyohimurium TA98 co—incubated with 7.7 uM
AF and increasing protein concentration of S9
preparations derived from rapid (RR) or slow (rr)
acetylator hamsters. Each data point is the Mean ± SD of
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Fig. 34. Mutagenic Activation of AF with Hamster Hepatic S9
Preparations. Mutagenicity of AF was assayed with —
Salmonella typhimurium TA98 co—incubated wIth 38.5 uM AF
and increasing protein concentration of hepatic S9
preparations derived from rapid (RR) or slow (rr)
acetylator hamsters. Each data point is the Mean ± SD of
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Fig. 35. Mutageriic Activation of AF with Hamster Hepatic S9
Preparations. Mutagenicity of AF was assayed with —
Salmonella tyohimurium TA98 co—Incubated with 77 uM AF
and increasing protein concentration of hepatic S9
preparations derived from rapid (RR) or slow (rr)
acetylator hamsters. Each data point is the Mean ± SD of
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Fig. 36. ConcentratIon—Dependent Mutagenicity of AF with Hamster
Hepatic S9 Activation in the Presence or Absence of
AcC0A. Mutagenecity of AF was assayed with Salmonella —
tv~himurium TA98 co—Incubated with hepatic S9 preparation
(1.1 mg/mi protein) derived from rapid (RR) or slow (rr)
acetylator hamsters, in the absence (—AcCoA) or presence
(+AcC0A) of 1 mM AcC0A. Each data point Is the Mean ± SD
of a determination of triplicate plates per treatment.























































































































































which may impact on the expression of NAT activity. Therefore,
supplementing hepatic S9 preparations with AcCoA enhances iii vitro
conditions for the expression of N—acetyltransferaSe activity.
There were no distinct differences in the depressed mutagenic
activation of AF between rapid and slow acetylator hepatic 89
preparations in the presence of 1 mM AcCoA (Fig. 36). However, when
supplemented with 5 mM AcCOA, initial results showed a marked difference
in the capacity of rapid and slow acetylator hepatic S9 preparations to
activate AF to mutagenic metabolites, with the slow acetylator
exhibiting the greater capacity (Fig. 37). This observation was
confirmed in other experiments (Fig. 40).
Effects of Increasing AcC0A Concentrations on the Mutagenic
Activation of AF with Hamster HeDatic S9 Preoarations
Dose—response studies in which hepatic S9 preparations were
supplemented with various concentrations of AcC0A consistently showed
higher number of TA98 revertants with S9 from slow acetylators compared
to rapid acetylators, either with 38.5 uM AF (Fig. 38) or 192 UN AF
(Fig. 39) in the reaction mixture. The AcC0A dose—dependent effect
appeared to saturate in the presence of about 5 mM AcC0A in the reaction
mix (Fig. 39).
FIg. 37. Concentration—Dependent Mutagenicity of AF with Hamster
Hepatic S9 Activation in the Presence or Absence of
AGC0A. Mutagenicity of AF was assayed with Salmonella —
tyDhimurium TA98 co—incubated with hepatic S9
preparations (1.1 mg/mi protein) derived from rapid (RR)
or slow (rr) acetylator hamsters, in the absence (—AcC0A)
or presence (+AcCoA) of 1 mM AcC0A. Each data point is
the Mean ± SD of a determination of triplicate plates
per treatment. The number of spontaneous revertants was




























0 51 ‘102 153 204
FIg. 38. Mutagenic Activation of AF with Hamster Hepatic S9
Preparations in the Presence of Various Concentrations of
AcCoA. Mutagenicity of Af (38.5 uM) was assayed with
Salmonella tvohlmurlum TA98 co—Incubated with hepatic 59
preparations (1 mg/mi protein) derived from rapid (RR) or
slow (rr) acetylator hamsters, in the presence of 0 to
10 mM AcC0A. Each data point Is the Mean ± SD of a
determinatIon of triplicate plates per treatment. The
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Fig. 39. Mutagenic Activation of AF with Hamster Hepatic S9
Preparations in the Presence of Various Concentrations of
AcCoA. Mutagenicity of AF (192 uM) was assayed with —
Salmonella tvDhimUrium TA98 co—incubated with hepatic S9
preparations (1 mg/mi protein) derived from rapid (RR) or
slow (rr) acetylator hamsters, in the presence of 0 to
10 mM AcCoA. Each data point is the Mean ± SD of a
determination of triplicate plates per treatment. The
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Fig. 40. Acetylator Genotype—Dependent Nutagenic Activation of
Various Concentrations of AF with Hamster Hepatic 59
Preparations in the Presence of AcCoA. Mutagenicity of AF
(0 to 200 uM) was assayed with Salmonella tyDhirnurium TA98
co—incubated with hepatlc 89 preparations (1 mg/mi
protein) derived from rapid (RR) or slow (rr) acetylator
hamsters, in the presence of 5 mM AcCoA. Each data point
is the Mean ± SD of a determination of triplicate plates
per treatment. The number of spontaneous revertants was
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Effects of Increasing Protein Concentrations of Heoatic S9
?i~parations On the Mutagenic Activation of AF
Initial AF mutagenicity assays had established an optimal condition
of about 1 mg/mi 89 in the absence of AcC0A (Fig. 35). In subsequent
dose—response studies in which the protein concentration of S9
preparations were varied, mutagenic activation of AF consistently
followed saturation kinetics. Although there was, generally, decreased
mutagenic activity in the presence of AcCoA, there was a greater
reduction In mutagenic activity with rapid compared to slow acetylator
hamster hepatic S9 preparations (Figs. 41 and 42).
Differential Modulation of AF Mutagerilcity With Heoatic S9
PreDarations Derived From Raoid and Slow Acetylator Hamsters
The results of dose—response studies in which the
concentrations of AF, AcC0A or S9 protein were varied suggested an
optimal assay condition, for comparing the relative capacity for
mutagenic activation with rapid or slow acetylator hepatic 89
preparations, composed of 200 UN AF, 5 mM AcC0A and 1 mg/ml S9 protein.
Under this assay condition, the capacity for mutagenic activation of AF
with slow acetylator hepatic S9 preparations were detemined to be
significantly (P 0.02) greater than with rapid acetylator 89
preparations (Table 10).
Fig. 41. Concentration—Dependent Mutagenic Activation of AF with
Various Protein Concentrations of Hamster Hepatic 59
Preparations in the Presence or Absence of AcCoA.
Mutagenicity of AF was assayed with Salmonella —
tv~h1murlum co—incubated with 200 uM AF, hamster hepatic
S9 preparations (0 to 1 mg/mi protein) derived from rapid
(RR) or slow (rr) acetylator hamster, in the absence (—
AcCoA) or presence (+AcCoA) of 5 mM AcC0A. Each data
point is the Mean ± SD of a determination of triplicate
plates per treatment. The number of spontaneous
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Fig. 42. Acetylator Genotype—Dependent Mutagenic Activation of AF
with Various Protein Concentrations of Hamster Hepatic 59
Preparations. Mutagenicity of AF was assayed with
Salmonella tyohimurium co—incubated with 200 UN AF,
hepatic S9 preparations (0 to 1 mg/mi protein) derived
from rapid (RR) or slow (rr) acetylator hamsters, in the
presence of 5 mM AcC0A. Each data point is the Mean ± SD
of a determination of triplicate plates per treatment.
The number of spontaneous revertants was about 10 to 15.
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Table 10. Relative Capacity for AF NAT Activity and Mutagenic
Activation of AF by Hamster Hepatic S9
Acetylator AF NAT Activ1ty~ Index of Modulation
genotype (nmol/min/mg) of Muta9enesig
(% Reversion)
RR 722 ± 4.2 14.4 ± 2.7
rr 6.7 ± 0.4 26.7 ± 2.2
aAF NAT activity determination is described in “Materials and
bMethods section.
Mutagenicity of AF was assayed with Salmonella tvohimurlum TA98 co—
incubated with 200 uM AF, 5 d4 ACC0A, and 1 mg/mi hepatic
S9 protein prepared from rapid (RR) or slow (rr) •acetylator
hamsters. Estimation of the index of modulation of mutagenic
activation of AF is described in “Materials and Methods” section.
The number of histidine (His) revertants with slow acetylator S9
is significantly (p ~ 0.02) higher than with rapid acetylator 39
and is indicative of greater modulation of mutagenic
activation by rapid acetylator S9..
CHAPTER V
DISCUSSION
The activity of the mammalian enzymes that catalyze the metabolism
of arylamines is an important endogenous factor that influences the
concentration of reactive metabolites in susceptible tissues and organs
and consequently, the magnitude of adverse biological effects exerted.
In man (reviewed in Weber, 1987),as well as several experimental
animals including hamsters (Hem et al., 1985; Hem et al., 1987a), the
rate of metabolism of arylamine drugs and carcinogens is subject to
large Interindividual differences due to the contribution of genetic
constitution of the N—acetyltransferase enzyme. The N—acetylation
polymorphism is a well known human genetic condition affecting the
pharmacokinetics of arylamine drugs and carcinogens. This polymorphism
provides a conceptual basis for the general hypothesis that species and
individual differences in the initiation of cancer might be related to
species and individual differences in the capacity to metabolize a




Occupational as well as environmental exposure to arylamines has
long been associated with the development of cancer, particularly
urinary bladder cancer in humans (Radomski et al., 1979; Lower, 1982;
Belan:d et al., 1983), but human exposure still persists. Although the
liver is recognized as the primary site for the activation of several
arylamine carcinogens (Miller and Miller, 1981), It has been observed
that the specific site for the occurrence of arylamine—induced cancer in
the urinary bladder is the transitional epithelium (Matanoski and
Elliot, 1981). It has recently been determined that metabolism of
arylamines also occurs in peripheral target tissues including the
bladder. Metabolic activities have been determined in tissue
preparations from lung (Cohen et al., 1976; Autrup et al., 1978),
mammary gland (Grover et al., 1980), gastrointestinal mucosa (Autrup et
al., 1978), skin (MacNicoll et al., 1980) and urinary bladder (Kadlubar
et al., 1977; Autrup et al., 1981; Uehleke et al., 1966; Hem et al.,
1987b; Mattano et al, 1988).
In another study by Oglesby et al. (1981), rat bladder epithelium
was found to exhibit rapid resorption of carcinogenic arylamines and
their metabolites, following direct instillation into the bladder.
Although the role of the non—epithelial tissue in the metabolic
activation and/or deactivation of arylamine carcinogens within the
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bladder tissue is still unknown, it could be a factor in the initiation
of bladder cancer. Equivalent levels of arylamine NAT activity were
detected in the epithelial and adjacent non—epithelial bladder tissues
of hamsters used in the study reported here. Acetylator genotype was
clearly expressed via levels of arylamine NAT activity in hamster
bladder epithelial and non—epithelial tissues. This observation
provided a valid basis for using whole bladder tissues in NAT
experiments . Thus, polymorphic N—acetylation of arylamines by either
or both tissues may modulate the genotoxic activation/deactivation of
arylamines or their electrophilic derivatives during arylamine—induced
bladder carcinogenesis.
Relatively high levels of arylamine NAT activity were expressed in
the urinary bladder cytosol of the inbred Syrian hamsters used in this
project. In addition, the levels of activity were acetylator genotype
dependent, confirming the results of previous hamster studies (Hem et
al., 1987b), as well as the observations made in rapid (C57BL/6J) and
slow (A/J) acetylator inbred mice (Mattano and Weber, 1987). The levels
of arylamine NAT activities in the inbred hamster were comparatively
higher than in the inbred mice and the differences in NAT activity
between the slow and rapid hamster strains were higher than was detected
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In the mouse strains. Furthermore, the acetylator genotype—dependent
expression of bladder NAT activity conformed to that of the liver which
is also known to be regulated by acetylator genotype (Hem et al., 1985;
Trinidad et al., 1989).
Several investigators have observed an association between bladder
carcinoma formation in humans and the acetylator status (Lower et al.,
1979; Cartwright et al., 1982; Evans et al., 1983). Slow acetylator
phenotypes appear to be more frequent among bladder cancer patients
compared to healthy control groups (Lower et al., 1979; Evans et al.,
1983; Hanssen et al., 1985). Although the complete metabolic pathway
for arylamine carcinogens is not yet known and the role of the liver in
extrahepatic carcinogenesis has been difficult to elucidate, different
mechanistic models have been proposed . A prevailing hypothesis for
arylamlne—induced bladder cancer assumes an active role for the bladder
urothelium in addition to, or as an alternative to hepatic metabolism.
It Is suggested that carcinogenic arylamines are N—oxidized in the liver
to activated proximate carcinogenic derivatives which are conjugated
with N—glucuronlde and transported via the kidney to the urinary
bladder. In addition to acid catalyzed hydrolysis which may occur in
the bladder lumen, proximate carcinogens may be interconverted by
enzymatic activities localized in the urothelium to generate
—~ —..—.
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activated/deactivated arylamine derivatives. N—acetylation reaction in
the bladder urothelium has been suggested to be a deactivation reaction
in the process of arylamine—induced bladder carcinogenesis (Lower,
1982). The association of slow acetylator phenotypes with increased
susceptibility to arylamine—induced bladder cancer appears to support
this hypothesis. However, a full understanding of the role of the
N—acetylation reaction in this phenomenon requires further
characterization of the enzyme—arylamine interactions.
Urinary bladder arylamine NAT activity in each of the slow and
rapid acetylator strains used in this study was partially purified into
two isozymes following anion—exchange FPLC of bladder cytosol. For each
homozygous rapid, heterozygous intermediate and homozygous slow
acetylator hamster, both NAT isozymes catalyzed AcCoA—dependent
N—acetylation of PABA, PAS, AF, ABP and BNA. The activity levels of the
first eluted isozyme were polymorphic and reflected acetylator genotype,
whereas the activity of the second isozyme , expressed independent of
the acetylator genotype, was monomorphic. The polymorphic NAT isozyme
Is thought to be responsible for the acetylator genotype—dependent
expression of bladder cytosol arylamine NAT activity. Polymorphic and
monomorphic NAT isozymes have also been isolated from liver cytosol
(Hem et al., 1985; Hem et al., 1986; Hem et al, 1987a; Kato and
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Yamazoe, 1988, Trinidad et al, 1989), intestine (Smith and Hanna,
1986), peripheral blood (Hem et al., 1986) of hamsters, as well as rat
(Wick and Hanna, 1986) and mouse (Hem et al., 1988) liver cytosol.
Polymorphic expression of AF, ABP and BNA NAT activities have also been
determined for bladder cytosols derived from a group of human organ
donors, but the distribution of PABA NAT activity appeared to be
monomorphic (Kirlin et al, 1989). Reports from studies using human
tissues seem to suggest that the regulation of human bladder NAT is
analogous to the regulation of hamster bladder NAT.
Pharmacokinetic characteristics of the partially purified hamster
bladder NAT Isozymes suggest a structural difference between the
polymorphic and monomorphic isozymes in rapid or slow acetylator hamster
bladder preparations, as opposed to a quantitative difference in the
same enzyme. This suggestion is supported by similar determinations in
rabbit (Hem et al., 1982; Andres and Weber, 1986), mouse (Mattano and
Weber, 1987) as well as the liver of hamster (Trinidad et al., 1989).
Thus, the polymorphic NAT gene locus in the hamster has been designated
~, with Pat’ representing the rapid allele and PatS representing the
slow acetylator allele (Hem, 1988b).
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There is a requirement for the metabolic activation of several
arylamines for the induction of bladder cancer in man as well as
experimental animals (Radomski et al., 1979; Miller and Miller, 1983).
Several studies have demonstrated that DNA damage, caused by
metabolically activated arylamines, is a critical factor in the
initiation of carcinogenesis (reviewed in Setlow, 1982). It Is assumed
that DNA binding to form arylamine—DNA adducts leads to genetic lesions
including mutations, chromosomal~ aberrations, tumor initiation and
conversion and ultimately neoplastic transformation of the cell (Sauza
et al., 1980; Miller and Miller, 1981). Assays which measure DNA
binding are often used in conjunction with mutagenesis assays in
evaluating chemicals for carcinogenic potentials and specificity. The
DNA binding assay can be a reliable probe of metabolic activation and
the cumulative impact of activation/deactivation reactions on the
production of metabolites over a period of time.
Activated arylamine derivatives bind to nucleic acids and adducts
are usually formed with deoxyguanosine (Beland et al., 1980). The
N—(deoxyguanosin—8—yl)—arylamine adduct species constitutes the major
adduct species formed in experimental animals (Beland et al., 1983;
Gupta et al., 1984), whereas acetylated adduct species are formed in
considerably lower amounts. Thus, the N—(deoxyguanosln—8—yl)—arylamine
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adduct species provides a convenient parameter for evaluating
differential levels of induction of DNA—arylamine adducts in hamsters of
different acetylator genotype. The detection and quantitation of DNA—
arylamine adducts require extremely sensitive methods because the level
of adducted nucleotides may be only 1 in i06 to 1 in or less of
normal nucleotides The use of the recently developed
[32P)—postlabeling thin layer chromatograpic technique (Randerath et
al., 1981; Gupta et al., 1982), is proving to be a very useful addition
to the assay methods available for detecting DNA adducts. This assay
technique has the advantage of being highly sensitive, eliminates the
need for radiolabeled arylamine carcinogens, and is applicable in the
detection of adducts formed from many arylamines (Reddy at al., 1984).
Using this assay technique, relatively high levels of DNA—AF and DNA—ABP
adducts were detected in hamster liver and bladder tissues, at 3 h and
18 h following treatment, but not In the tissues of untreated hamsters.
In a comparative study of arylamine—induced adduct levels in mice, that
was reported earlier, detectable levels of DNA—AF adducts were
determined in the liver of mice, 3 h after administration of a 60 mg/kg
body weight dose of AF (Levy and Weber, 1989). The mouse study utilized
the HPLC chromatography technique for resolving adducted nucleotides and
found higher adduct levels in the tissues of rapid acetylator than in
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slow acetylator mice. In another study, using the UDS assay technique
to determine the relationship between acetylation rates in rabbit
hepatocytes and their susceptibility to genotoxicity induced by AF,
hepatocytes from rapid acetylators were more sensitive than those from
slow acetylators and displayed greater amounts of DNA damage (McQueen et
al., 1982). The amount of DNA repair In hepatocytes was measured at 18
h following treatment in this rabbit study. The hepatic DNA levels
detected in hamsters used in the present study, 3 h following treatment,
did not show any significant (p>0.1) difference between the rapid and
slow acetylator hamsters tested.
Studies of macromolecular binding of arylamines have shown maximal
binding to DNA at about 24 h following injection into experimental
animals and a striking common feature was the persistence of the lesions
induced by this binding (Beland et al., 1979; Martin and Ekers, 1980;
Visser and Westra, 1981). Relatively long—term exposure to
carcinogenic arylamines before assaying for adduct levels induced in
hamsters, maximizes the impact of activation reactions and the
potentially deactivating activities of the N—acetylation reaction jj~
vivo. This rationale was confirmed in the results of this study when
hamster tissues were examined for DNA adduct levels 18 h following acute
treatment. Hepatic DNA—AF and DNA—ABP adduct levels in slow acetylator
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hamsters were significantly (p~O.OO1 and p:O.003, respectively) higher
than in rapid acetylator hamsters, 18 h following treatment.
The generation of adducts in the bladder urothelium involves a more
complex process compared to the liver. Although the adduct levels
detected in the bladders of hamsters used in this study were generally
lower than hepatic adduct levels, rapid acetylators expressed higher
adduct levels compared to the slow acetylator. The levels of
arylamines, acetylated or non—acetylated arylamine derivatives reaching
the bladder at 3 h or 18 h following the treatment regimen used in the
present study were not determined. It is, however, conceivable that the
concentrations of these chemical species reaching the bladder would
affect the levels of DNA adducts formed in the bladder. The results of
the hepatic adduct levels detected in hamsters 18 h following treatment
suggest that the capacity for N—acetylation may play a significant role
in the susceptibility to arylamine—induced genotoxicity. The
significance of the relatively low adduct levels generated in hamster
bladder compared to the liver is still not clear. In addition, the role
of acetylator genotype on the levels of DNA adducts generated in the
bladder of the hamsters used in the present study remains to be fully
determined.
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The N—hydroxyaryIamines generated by the metabolic activation of
arylamines are known to readily react with biological macromolecules
including DNA, as well as acting as direct mutagens (Poirier and de
Serres, 1979). The arylamine derivative is also thought to be a
proximate carcinogen responsible for the induction of bladder
carcinogenesis. The N—acetylation reaction is thought to compete with
the oxidation reaction responsible for generating N—hydroxyarylamines.
Among untreated animals, the Syrian hamster provides the most sensitive
and consequently, the most preferential activating system for
nitrosamines, heterocyclic amines and arylamines (Felton et al., 1981;
Phillipson and loannides, 1983). The Ames mutagenicity assay is used
extensively to screen for mutagenic and hence carcinogenic chemicals
including arylamines, employing mammalian S9 preparations as a metabolic
activating system (Ames, 1979). Most arylamines that are mutagenic in
the Ames Salmonella test are also known carcinogens (Ames et al., 1973;
Ames et al., 1975; McCann and Ames, 1975). A high empirical correlation
has also been measured between genotoxicity in bacteria and
mutagenicity/carcinogenicity in higher organisms (Leifer et al., 1981).
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Most arylamines require metabolic activation In order to exert
their genotoxic effects (Miller ,1970). It is therefore thought that
interindividual variation in hepatic arylamine metabolizing enzymes iii
viva or jj3. vitro may form a basis for differences in the capacity for
genotoxic activation of arylamines. The variations in hepatic adduct
levels detected between rapid and slow acetylator hamsters appear to
support this concept, whereby the N—acetylation reaction modulates the
genotoxic activation of carcinogenic arylamines j~ viva, in a manner
dependent on acetylator genotype. Since the inbred hamster model used
in this study expressed distinctly different N—acetylation capacities
and N—acetylation reaction appears to be a detoxification reaction in
certain arylamine—induced carcinogenesis, it was of interest to
determine the relationship between acetylator genotype with the
mutagenic activation of AF by S9 preparations derived from rapid and
slow acetylator hamsters. Quantitative differences were observed in the
capacities of S9 preparations derived from homozygous rapid or
homozygous slow acetylator hamsters to mediate the mutagenicity of AF in
Salmonella tvDhimurlum TA98, when the S9 preparation was supplemented
with AcC0A. The mutagenic activation of AF by S9 preparations derived
from rapid or slow acetylator hamsters exhibited saturation kinetics and
did not differ between acetylator genotype when the assay was conducted
142
In the absence of AcC0A. AcC0A is a required cofactor for the
expression of NAT activity iii vivo or Jia vitro. Generally, the presence
of AcC0A in the reaction mixture resulted In a dose—dependent reduction
In the mutagenic activation of AF. This reduction suggests that the
N—acetylatlon reaction Is competing with the N—oxidative activation of
AF in the assay condition. The NAT activity In the S9 preparations were
determined to be resistant to paraoxon, a known inhibitor of microsomal
deacetylase. Thus, the same cytosolic NAT activity determined by
acetylator genotype was responsible for modulating the j~ vitro
mutagenicity of AF.
32The findings of this study were able to show, by [ Pi—postlabeling
assay of DNA adducts induced j~ vivo and Ames Salmonella test for iii
vitro mutagenic activation of arylamine, that the acetylator genotype of
hamsters can modulate the genotoxic activation of arylamine carcinogens.
This modulation was reflected in greater reduction of genotoxicity in
rapid acetylator hamsters, but higher genotoxic activation in the slow
acetylator. The effect of acetylator genotype on arylamine—induced
genotoxicity in hamsters appears to conform with the genetic




1. Equivalent levels of PABA and AF NAT activities are expressed in
hamster bladder epithelial and epithelium—depleted cytosolic
preparations and acetylator genotype is expressed via levels of
NAT activity in both tissues..
2. Hamster bladder cytosol expresses PABA, PAS, AF, ABP and BNA NAT
activity that are acetylator genotype—dependent, with highest
levels expressed in homozygous rapid acetylator, intermediate
levels in heterozygous Fl acetylator progeny and lowest levels
in homozygous slow acetylator hamsters. This genotype—dependent
capacity for arylamine N—acetylatlon is consistent with simple
autosomal Mendelian inheritance of two codominant alleles at
a single gene locus.
3. The apparent Vmax of PABA NAT activity in homozygous rapid
acetylator bladder cytosol is about 14—fold greater than in
homozygous slow acetylator hamster bladder cytosol.
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4. The apparent Vmax of AF NAT activity in homozygous rapid
acetylator bladder cytosol is about 6—fold greater than in
homozygous slow acetylator hamster bladder cytosol.
5. Two isozymes of AcCoA—dependent arylamine NAT activities were
partially purified by anion—exchange FPLC of bladder cytosol
derived from homozygous rapid or homozygous slow acetylator
hamsters. The first eluting Isozyme exhibits an acetylator
genotype—dependent NAT activity for PABA, PAS, AF, ABP, BNA and
is referred to as the polymorphic isozyme, while the second
isozyme exhibits acetylator genotype—independent NAT activity
for the same substrates and Is thus referred to as the
monomorphic i sozyme.
6. The apparent Vmax of AF NAT activity via the polymorphic isozyme
is about 50—fold higher in rapid acetylator than in the slow
acetylator hamster.
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7. The apparent Vmax of AF NAT activity via the monomorphic isozyme
is not significantly (p>O.05) different from enzyme preparations
derived from rapid acetylator or slow acetylator hamster bladder
cytosol.
8. The apparent Km of NAT for PABA is about 3—fold higher in the
bladder cytosol derived from slow acetylator hamsters than in
rapid acetylator cytosol.
9. The apparent Km of NAT for AF is consistently higher In the
enzyme preparations derived from homozygous rapid acetylator
hamsters than in those of homozygous slow acetylator hamsters,
and the variations in the values for the polymorphic
Isozymes (168 ± 83.00, 8.71 ± 6.63 micromolar) and monomorphic
isozymes (6.32 ± 2.17, 0.68 ± 0.21 micromolar) determined in
each of the acetylator genotypes, respectively, is consistent
with the polymorphic and monomorphic isozymes expressed as
structural variants in each genotype.
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10. The pharmacokinetic constants determined for hamster bladder
AcC0A—dependeflt arylamine NAT activity, in crude cytosol and
with the polymorphic isozyme and monomorphic isozyme, are
concordant with acetylator genotype—dependent arylamine NAT
activity in hamster liver.
11. The levels of N—(deoxyguanosln—8—Yl)—2—amiflOflUorefle and
—4—aminobiphenyl adducts formed in the livers of homozygous
rapid and homozygous slow acetylator hamsters, 3 h following a
single i.p. dose (60 mg/kg body weight) of AF, did not differ
between the two acetylator genotypes.
12. The levels of N—(deoxyguanosin—8—yl)—2—amiflOflUOrefle or
—4—aminobiphenyl adducts formed In the livers of homozygous
slow acetylator hamsters, 18 h following a single 1.p.
(60 mg/kg body weight) were about 1.5—fold and 2.3—fold higher,
respectively, than in homozygous rapid acetylator hamsters.
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13. The levels of N—(deoxyguanosin—8—yl)—2—aminofluorene or
—4—aminobiphenyl adducts formed in the bladders of homozygous
rapid acetylator hamsters were both about 1.6—fold higher than
in homozygous slow acetylator hamsters.
14 Mutagenic activation of AF by hamster hepatic S9 preparations,
in the absence of AcC0A, exhibits saturation kinetics which does
not differ between the rapid or slow acetylator genotypes.
15. Mutagenic activation of AF by hepatic S9 preparations in the
presence of various concentrations of AcCoA, a cofactor required
for the expression of arylamine NAT activity, results in a dose—
dependent reduction in the mutagenic activation of AF, but the
rapid acetylator S9 preparation expresses greater reduction of
mutagenic activity than the slow acetylator S9.
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16. Mutagenic activation of AF by various protein concentrations of
hepatic 89 preparations, in the presence of AcCoA, exhibited a
depressed saturation kinetics, but rapid acetylator S9
preparations expressed a greater depression of mutagenic
activation than the slow acetylator S9.
17. Mutagenic activation of AF with hepatic S9 preparations derived
from homozygous rapid or homozygous slow acetylators, in the
presence of AcC0A and various concentrations of AF, exhibited a
depressed saturation kinetics, but rapid acetylator 89
preparations expressed a greater depression of mutagenic
activity than the slow acetylator S9.
18. The effect of acetylator genotype on the levels of hepatic DNA—
arylamine adducts, determined 18 h following treatment, as well
as on the mutagenic activation of AF by hepatic S9 preparations,
are consistent with higher incidence of arylamine—induced
bladder cancer in human slow acetylators.
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